The Global African Swine Fever Research Alliance (GARA) aims to expand ASF research collaborations worldwide and maximize the use of resources and expertise to achieve its five strategic goals:

1. To facilitate research collaborations and serve as a communication gateway for the global ASF research community.
2. To conduct strategic research to increase our understanding of ASF.
3. To develop the next generation of control measures and strategies for their application.
4. To determine social and economic impacts of the new generation of improved ASF control.
5. To provide evidence to inform development of policies for safe trade of animals and animal products in ASF-endemic areas.

Additional information on the GARA and the work of the alliance can be found on the following website: http://www.ars.usda.gov/GARA

The purpose of this ASF Gap Analysis Report is to assess current scientific knowledge and the available countermeasures to effectively control and mitigate the impact of an ASF outbreak in countries experiencing outbreaks, and also support global control and eradication initiatives in ASF-endemic countries.

This ASF Gap Analysis Report is the compilation of four workshops organized by the GARA with the support of its partners.

To cite this report:
Global African Swine Fever Research Alliance (GARA) Gap Analysis Report. 2018:
https://go.usa.gov/xPfWr
<table>
<thead>
<tr>
<th>CONTENTS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>EXECUTIVE SUMMARY</td>
<td>5</td>
</tr>
<tr>
<td>GROUP PICTURES</td>
<td>8</td>
</tr>
<tr>
<td>GLOSSARY</td>
<td>12</td>
</tr>
<tr>
<td>INTRODUCTION</td>
<td>13</td>
</tr>
<tr>
<td>BACKGROUND</td>
<td>15</td>
</tr>
<tr>
<td>GARA Gap Analysis Workshops</td>
<td>15</td>
</tr>
<tr>
<td>Reference Material</td>
<td>15</td>
</tr>
<tr>
<td>DEFINITION OF THE THREAT</td>
<td>16</td>
</tr>
<tr>
<td>Economic Impact</td>
<td>16</td>
</tr>
<tr>
<td>Epidemiology</td>
<td>16</td>
</tr>
<tr>
<td>Surveillance</td>
<td>16</td>
</tr>
<tr>
<td>Biosecurity</td>
<td>17</td>
</tr>
<tr>
<td>Depopulation</td>
<td>17</td>
</tr>
<tr>
<td>Vaccines</td>
<td>17</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>18</td>
</tr>
<tr>
<td>GAP ANALYSIS</td>
<td>19</td>
</tr>
<tr>
<td>Virology</td>
<td>19</td>
</tr>
<tr>
<td>Pathogenesis</td>
<td>25</td>
</tr>
<tr>
<td>Immunology</td>
<td>29</td>
</tr>
<tr>
<td>Vaccines</td>
<td>33</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>36</td>
</tr>
<tr>
<td>Epidemiology</td>
<td>43</td>
</tr>
<tr>
<td>Surveillance</td>
<td>46</td>
</tr>
<tr>
<td>Feral Swine and wild Suidae</td>
<td>47</td>
</tr>
<tr>
<td>Tick Vector</td>
<td>47</td>
</tr>
<tr>
<td>COUNTERMEASURES ASSESSMENT</td>
<td>48</td>
</tr>
<tr>
<td>ASSUMPTIONS</td>
<td>48</td>
</tr>
<tr>
<td>DECISION MODEL</td>
<td>49</td>
</tr>
<tr>
<td>Vaccines</td>
<td>51</td>
</tr>
<tr>
<td>Diagnostics</td>
<td>52</td>
</tr>
<tr>
<td>Disinfectants/Inactivation</td>
<td>55</td>
</tr>
<tr>
<td>Acaricides</td>
<td>55</td>
</tr>
<tr>
<td>Drugs</td>
<td>56</td>
</tr>
<tr>
<td>Personal Protective Equipment (PPE)</td>
<td>56</td>
</tr>
<tr>
<td>RECOMMENDATIONS</td>
<td>57</td>
</tr>
<tr>
<td>RESEARCH</td>
<td>57</td>
</tr>
<tr>
<td>PREPAREDNESS</td>
<td>60</td>
</tr>
<tr>
<td>CONCLUSION</td>
<td>61</td>
</tr>
</tbody>
</table>
EXECUTIVE SUMMARY

The Global African Swine Fever Research Alliance (GARA) organized four scientific conferences from 2013 to 2016 to conduct gap analyses of our current knowledge and the available veterinary medical countermeasures to effectively control and mitigate the impact of a disease outbreak caused by African swine fever (ASF).

The key and consistent conclusion from these workshops is that although ASF has historically been confined to the continent of Africa, the risk of an introduction of ASF in Europe, North America, South America, Eurasia, or Asia is significant and would be economically devastating. African swine fever is one of the most complex viral diseases affecting domestic pigs, wild boars, and wild suids. Soft ticks are considered a biological reservoir and transmission vector. African swine fever virus (ASFV) usually induces an unapparent infection in a variety of African warthog and bush pig populations.

Currently ASF is endemic in more than twenty sub-Saharan African countries and 16 new introductions have been declared since the report of an outbreak in the Caucasus region in 2007, affecting Georgia, Armenia, Azerbaijan, Russia, Baltic Sea countries, and Eastern and Central Europe. In 2018, ASF continued to spread towards Western Europe. And 2018, China reported its first ASF outbreak. The disease situation in these countries has not improved, thus increasing the ASF risk of spread towards other countries.

The initial expression of ASF in swine is variable and unpredictable due to the myriad of host factors and the broad diversity of virulence among ASF virus isolates. Viral mechanisms involved in induction of disease, tissue tropism, host range, and induction of immune responses are still not well understood. The disease occurs in several forms, ranging from acute lethal to chronic clinical disease. Thus, clinical diagnosis is almost impossible and has to be supplemented with reliable laboratory tools. Antibody response elicited by infection with highly virulent strains of the virus does not begin to appear at detectable levels until at least 7-14 days post infection, which can make early detection difficult and a challenge for surveillance programs. However, combining viral genome and antibody detection provides reliable diagnosis from the end of the incubation period, or even a little earlier.

The GARA determined that the following countermeasures were important but several weaknesses were identified.

Surveillance
Routine surveillance for early detection is the first line of defense against a disease outbreak. Rapid and accurate detection affects the time when control measures can be implemented and affects the extent of the disease outbreak. Viral strains of ASF can vary from low to highly virulent; and clinical signs range from persistent infections with no apparent signs in endemic countries to outbreaks of acute infection and severe disease in previously ASF-free countries. The initial expression of ASFV in swine in an ASF-free country like the U.S could be variable and unpredictable due to the myriad of factors including the epidemiology of ASF and the broad diversity of virulence among ASF virus isolates. Historically there have been at least two
surveillance programs in place: 1) a ‘syndromic’ surveillance program based on reporting of clinical signs and 2) a laboratory-based surveillance program that includes diagnostic testing of populations at risk. Recent experience with ASF outbreaks due to the smuggling of contaminated feed strongly warrants the onset of a new branch of testing and validating methods to detect ASFV in foods, food scraps, and agricultural processed products as part of the laboratory-based surveillance programs. However, caution with this kind of testing needs to be considered due to vulnerabilities associated with sampling size and the fact that a negative result does not tell you anything, while conversely a viral genome positive result does not provide sufficient information to judge the true risk of a possible introduction.

**Depopulation**

Depopulation is the primary countermeasure to reduce virus shedding and stop the spread of ASF virus. Minimum control measures will include depopulation of infected herds, surveillance and movement restriction within established control zones together with surveillance in herds that have been in contact with infected herds. Depopulation of contact herds and neighboring herds might be established. However, this method of control results in significant financial implications and the culling of thousands of animals has also become ethically debatable. The effectiveness of stamping out in the absence of a fair and timely compensation scheme is highly dubious; i.e., in the absence of compensation there is no incentive for pig owners to report, who will instead sell or slaughter their pigs further spreading the disease. There is a need to come up with sustainable and effective alternatives to stamping out for countries that cannot afford compensation.

**Biosecurity**

On-farm biosecurity is a critical countermeasure for preventing the introduction and spread of ASF. Optimal biosecurity is effective by controlling the movement of pigs, people, equipment and supplies, and the potential biological or mechanical carriers of ASF. Priority biosecurity measures include the banning of swill feeding and the containment of scavenging pigs, which may be a challenge in developing countries. The identification of the source of transmission and entry into a target herd is a critical step in the implementation of an effective biosecurity program. However, after measures to curtail the spread of the disease are implemented, the most likely routes of transmission of ASFV may change. Since ASFV is an Arbovirus, a biosecurity plan should address procedures for cleaning and disinfecting facilities when Ornithodoros ticks are present; although a comprehensive biosecurity plan should include the control of insects and pests. Animal contacts as source of the virus may decrease, and transport trucks, people contacts, and pick-up for rendering services may contribute equally in the spread of the disease between premises. In endemic areas like Africa, the ideal solution for commercial pig farms has been the use of compartmentalization and has been used successfully in ASF control areas.

**Vaccines**

There is currently no commercial vaccine available for ASFV. In fact, an effective commercial vaccine for ASF has never been successfully developed. Although not formally classified, ASF scientists know there is a lack of cross protection among animals becoming immune to a certain virus isolate and subsequently exposed to another heterologous strain. This constitutes an important issue that will need to be addressed by both the ASF research community and veterinary authorities when considering vaccination strategies for the control and eradication of
ASF. If vaccination of wild boar populations is considered, only safe, live-attenuated vaccines may be feasible.

**Diagnostics**
African swine fever is usually suspected based on clinical signs, but clinical evidence may be nonspecific and difficult to differentiate from other infectious diseases of swine; e.g., Classical Swine Fever. Diagnosis is based on a combination of a pathogen detection test such as PCR and a serological test for specific antibodies, usually performed by ELISA. In industrialized countries, both detection tools are commercially available and allow disease detection from three to four days post infection by PCR, and roughly day 7 to 14 by ELISA. Confirmatory tests are so far not commercially available.
2nd GARA Gap Analysis Workshop
ARC - Onderstepoort Veterinary Institute
Pretoria, South Africa
November 11-14, 2014
3\textsuperscript{nd} GARA Gap Analysis Workshop
ANSES - Laboratoire de Ploufragan-Plouzané
Ploufragan, France
September 6-8 2016
4th GARA Gap Analysis Workshop
Istituto Zooprofilattico Sperimentale
Cagliari, Sardinia, Italy
April 11-13, 2018
**GLOSSARY**

AHT: Animal Health Technician

APHIS: Animal and Plant Health Inspection Service

ARS: Agricultural Research Service

BSL: BioSafety Level

ELISA: Enzyme-linked immunosorbent assay

ASF: African swine fever

ASFV: African swine fever virus

DIVA: Differentiating between infected and vaccinated animals

FADDL: Foreign Animal Disease Diagnostic Laboratory

GMP: good manufacturing practice


Ig: Immunoglobulin

MLV: Modified live virus vaccine

NAHLN: National Animal Health Laboratory Network

NVS: National Veterinary Stockpile

OIE: World Organization for Animal Health

PCR: Polymerase Chain Reaction.

qPCR: Real-time PCR

cPCR: Conventional PCR

PPE: Personal Protective Equipment
INTRODUCTION

African swine fever (ASF) is a contagious viral disease of domestic pigs with significant economic consequence. In Africa, ASF virus (ASFV) produces unapparent infections in wild suids: wart hog (*Phacochoerus africanus*), bush pigs (*Potamochoerus larvatus, P. porcus*) and the giant forest hog (*Hylochoerus meinertzhageni*) (a single report). The reservoir of ASFV is considered the soft tick *Ornithodoros moubata* (Dixon *et al.*, 2005).

African swine fever virus is a large enveloped virus containing a double stranded (ds) DNA of approximately 190 kilobase pairs. African swine fever virus shares aspects of genome structure and replication strategy with other large dsDNA viruses, including the *Poxviridae, Iridoviridae*, and *Phycodnaviridae*. Although initially classified as an iridovirus, based largely on virion morphology, increasing knowledge of ASFV molecular biology led to its reclassification as the sole member of a new DNA virus family, *Asfarviridae* (*Asfar, African swine fever and related viruses*) (Costard *et al.* 2009).

African swine fever virus infections in domestic pigs are often fatal and are characterized by fever, hemorrhages, ataxia and severe depression. However, the course of infection varies depending on host characteristics and the particular virus strain. African swine fever occurs in several forms, ranging from highly lethal to sub-clinical. Acute forms of ASF, associated with highly virulent ASF strains, are characterized by high fever, purple discoloration of the skin, multiple hemorrhages, respiratory distress, incoordination and death 3 to 7 days post-infection. Only a low percentage of animals will survive. Sub-acute and chronic forms of the disease are characterized by high fever, staggering gait, cough, diarrhea, purple discoloration of the skin, and death in 20 to 45 days post infection. These forms are accompanied by a higher proportion of surviving animals, and can be associated with ASFV strains of moderate and low virulence, respectively (Sánchez-Vizcaíno *et al.* 2015a).

African swine fever was considered a disease of sub-Saharan Africa. However, in 1957, ASF was introduced into Portugal and later on to other European countries and some States of Central and South America. From Europe, ASF was eradicated at the end of the 1990s with the exception of the Italian island of Sardinia. Eradication was also achieved in the other affected countries outside Europe. However, in 2007, a very virulent viral strain of ASF was introduced into the Republic of Georgia, probably through untreated food waste from international ships in the harbor of Poti. Subsequently, the virus (Georgia 2007) started to spread in the Trans-Caucasian region and reached the Russian Federation. From the beginning, this new introduction affected both domestic pigs and European wild boar. The latter proved to be as susceptible as domestic pigs and the disease established self-sustaining cycles within the wild boar population. This was unprecedented as so far, any previous introduction into the European wild boar population had been self-limiting, unless sustained by co-infection and spillover from domestic pigs. From Russia, the virus moved further and reached the European Union in 2014. At present, all Baltic EU Member States, Poland, Romania, Bulgaria, Hungary, and Belgium are affected. Moreover, a limited outbreak occurred among wild boar in Czech Republic. The latter was declared as resolved very recently. In August 2018, the disease also reached the world’s largest pig producer, China. Thus, the disease has conquered three continents over the last
decade. In consequence, the transboundary disease threat has now an unprecedented geographical scope and its multi-sectoral nature necessitates inclusion of all stakeholders into the design of control measures (OIE, ASF Handbook).

Countries free of ASF currently employ isolation and preemptive slaughter of animals in outbreak areas. Although effective, isolation and preemptive slaughter result in huge economic losses (Arias and Sanchez-Vizcaino 2002). There is no available vaccine against ASF. Consequently, detection and elimination of infected animals is so far the only methodology to control and eradicate ASF (Costard et al. 2009).
BACKGROUND

**GARA Gap Analysis Workshops**
This gap analysis report is the compilation of gap analyses conducted during scientific conference organized by the GARA 2013-2018:

1\textsuperscript{st} GARA Scientific Conference, Plum Island Animal Disease Center, Orient Point, New York, United States of America, April 6-8, 2013

2\textsuperscript{nd} GARA Scientific Conference, Agricultural Research Council, Pretoria, South Africa, November 10-14, 2014

3\textsuperscript{rd} GARA Scientific Conference, ANSES, Ploufragan, France, September 6-8, 2016

4\textsuperscript{th} GARA Scientific Conference, Istituto Zooprofilattico Sperimentale, Cagliari, Sardinia, Italy, April 11-13, 2018

The gap analyses conducted by ASF experts were determined both by presented research updates reported from 44 research institutes from 34 different countries from across the world, coupled with scientific literature reviews. Using this information, priority areas for ASFV research were determined.

**Reference Material**
The GARA recommends the following websites and reports as background information on the biology, epidemiology, and control of ASF:

DEFINITION OF THE THREAT

The current threat for an introduction of African swine fever (ASF) into new geographical locations has never been higher. Since the introduction of ASF into the Republic of Georgia in 2007, 16 countries outside Africa have reported ASF outbreaks (Table 1). With the continued spread of ASF in Africa, Russia, Europe, and now China, there is an unbroken perpetual threat of introducing ASF in previously ASF-free countries. Potential routes of infection include 1) the importation of infected pig products fed as contaminated swill to domestic pigs, 2) the spread of the virus to new geographical areas from infected pigs and wild boars, and 3) accidental or intentional nefarious events.

ECONOMIC IMPACT

The introduction of ASF into countries outside Africa has had important economic consequences for swine industries. A significant consequence of the introduction of ASF is the loss of status for international trade and the implementation of drastic and costly control strategies to eradicate the disease (Costard et al., 2009). In Cuba, the introduction of the disease in 1980s led to a total cost of U.S $9.4 million (Simeon-Negrin and Frias-Lepoureau 2002). In Spain, the final 5 years of the eradication program alone were estimated to have cost $92 million (Arias and Sanchez-Vizcaino 2002). Given the effect on pork production and trade as well as the costs of eradication, Rendleman and Spinelli estimated in 1994 that the net benefit of preventing ASF introduction in the United States would amount to almost $450 million, nearly 5 per cent of the value of total sales of pork products. In endemic countries, ASF has huge economic implications both for the individual farmers, especially the smallholder producers and at national scales (Fasina et al., 2012). In Africa the impact is also considerable, particularly on numerous poor households that depend on pigs to pay for many of the necessities of life.

EPIDEMIOLOGY

African swine fever may show unique regional patterns of presentation, associated with unique set of risk factors that should be assessed to establish proper surveillance and control strategies. The epidemiology of ASF varies depending on two types of transmission cycles among swine populations, which can be defined as a domestic pig cycle and sylvatic-wild pig cycle. To this, an additional cycle has been added: the environmental cycle, which includes the issue of wild boar and persistence in the environment as observed in the Baltics and Central Europe. The initial expression of ASF in a previously ASF-free country could be variable and unpredictable due to the myriad of host factors and the broad diversity of virulence among strains of ASF viruses. Additionally, the presence of competent arthropod vectors may also impact the maintenance of the virus in the environment.

SURVEILLANCE

Surveillance is the most important countermeasure to be able to eliminate the disease at the source through early detection and containment of a disease outbreak. However, different surveillance strategies are required to detect the different clinical manifestations resulting from ASFV infections. For acute infection, surveillance activities can be based on clinical signs; however, for mild cases or chronic infections, where recognition of ASF symptoms is less likely, surveillance activities must be based on diagnostic testing to supplement surveillance based on
clinical signs. Passive surveillance is often the only economically viable solution for many countries but has weaknesses due to the difficulty of differentiating ASF from many common endemic infectious diseases. Passive surveillance can be greatly improved by awareness campaigns targeting all stakeholder along the pig value chain, as well as the establishment of fair compensation plans to incentivize reporting. Active surveillance programs are expensive and currently must rely on direct diagnostic tests such as viral isolation and nucleic acid-based assays because of challenges and weaknesses of antibody-based assays.

**Biosecurity**
Implementing biosecurity measures on the farm is one of the most important countermeasures to prevent and protect commercial swine operations, but specific measures need also to be included and integrated in an eradication campaign to prevent further transmission and geographical spread through transport and person-to-person contacts. The main goal of a biosecurity plan is to decrease the probability of infection and significantly reduce the cost associated with losses (Fasina et al., 2012). A set of zoo-sanitary measures should be put in place to accomplish the goals set by the biosecurity plan. The more measures are implemented, the higher the cost, but warranted in a disease outbreak situation (Fasina et al., 2012). The OIE Terrestrial Animal Health Code (Chapter 15.1 and Chapters 4.3 and 4.4) provides guidelines for the establishment of compartments free of ASF.

**Depopulation**
Depopulation is the primary countermeasure to reduce virus shedding and stop the spread of ASF virus. Minimum control measures will include depopulation of infected herds, surveillance and movement restriction within established control zones together with surveillance in herds that have been in contact with infected herds. Depopulation of contact herds and neighboring herds might be established. Thus, this method of control has resulted in significant financial implications and the culling of thousands of animals has also become ethically debatable. The effectiveness of stamping out in the absence of a fair and timely compensation scheme is highly dubious; i.e., in the absence of compensation there is no incentive for pig owners to report, who will instead sell or slaughter their pigs further spreading the disease. Lack of funds to compensate owners, particularly for culling of healthy pigs on neighboring premises, also constitutes a challenge in less wealthy countries. There is a need to come up with sustainable and effective alternatives to stamping out for countries that cannot afford compensation. When implemented, the speed of depopulation of infected herds including disposal of carcasses, and disinfection of premises may have an effect on disease spreading, duration of the outbreak, and overall effectiveness of the control measure (Boklund et al., 2009). This control measure is effective in countries or geographic areas where pigs are housed in well-defined premises or pig farms. In areas where domestic pigs are kept on free-ranging scavenging systems, depopulation might be difficult.

**Vaccines**
There is no vaccine available for ASF and the control of the disease is strictly dependent on animal quarantine, biosecurity measures, and slaughter. This presents a major gap in the availability of veterinary medical countermeasures to effectively prevent, control, or eradicate an ASF outbreak. Some of the challenges in developing a vaccine include the following technical hurdles: 1) ASFV is one of the largest DNA virus known with the large majority of the viral
genes uncharacterized or known functions; 2) there are no cell lines readily available to grow ASFV for vaccine production; 3) there are several ASFV genotypes with different phenotypic characteristics, with little or no cross-protection demonstrated amongst experimental vaccines tested to date; 4) vaccine are needed for parenteral administration for domestic pigs, and oral administration to vaccinate feral swine and wild boars, and potentially other wild suids where a sylvatic cycle exists, although wild suids in Africa are known to be fairly resistant to ASF viruses.

**DIAGNOSIS**
ASF is usually suspected based on clinical signs, but clinical evidence may be nonspecific and difficult to differentiate from other endemic infectious diseases and transboundary diseases such as classical swine fever. Real time and conventional PCR used simultaneously with ELISA antibody testing is an important tool for this purpose. Serological and virological differentiation of other etiological agents producing ASF-like diseases is critical. Available ELISA tests are particularly useful if a large number of samples have to be examined. There is a need for useful pen side tests that can be used in an outbreak situation to make rapid decisions in the field about the status of a test herd.
GAP ANALYSIS

The following section summarizes what we know about African swine fever virus, gaps in our knowledge, and research needs.

**Virology**

African swine fever virus (ASFV) is a large, enveloped virus containing a double stranded (ds) DNA of approximately 190 kilobase (Kb) pairs. ASFV encodes novel genes involved in host immune response modulation, viral virulence for domestic swine, and in the ability of ASFV to replicate and spread in its tick vector. ASFV shares aspects of genome structure and replication strategy with other large dsDNA viruses, including the Poxviridae, Iridoviridae, and Phycodnaviridae (Dixon *et al.*, 2000 and 2008). ASFV and poxviruses replicate in the cytoplasm of the infected cell, primarily in discrete perinuclear assembly sites referred to as virus factories. They also exhibit temporal regulation of gene expression and have similar genome structures, including terminal inverted repeats, terminal crosslinks, a central conserved region and variable regions at each end of the genome (Dixon *et al.* 2008). Although initially classified as an iridovirus based largely on virion morphology, increasing knowledge of ASFV molecular biology led to its reclassification as the sole member of a new DNA virus family, Asfarviridae (Asfar, African swine fever and related viruses) (Dixon *et al.* 2000).

The ASFV virion is comprised of more than 50 polypeptides and has a complex but regular structure by electron microscopy, icosahedral in symmetry and containing several concentric layers for an overall diameter of approximately 200 nm (Breese and DeBoer 1966; Carrascosa *et al.*, 1984, 1985; Estevez *et al.*, 1986 and 1987; Schloer, GM, 1985). The 80-nm virion core is composed of a nucleoid, (Andres *et al.*, 1997 and 2002). Surrounding the nucleoid are two lipid bilayers, (Andres *et al.*, 1997 and 1998; Rouiller *et al.*, 1998). External to the inner membrane is the capsid, composed of the structural protein p72 (also referred to as p73), which comprises approximately one-third the protein content of the virion, and providing the icosahedral structure to the virion (Andres *et al.*, 1997; Carrascosa *et al.*, 1986; Garcia-Escudero *et al.*, 1998; Tabares *et al.*, 1980a). Covering the capsid is a loose external membrane obtained by virion budding through the plasma membrane, which is not required for virus infection (Andres *et al.*, 2001; Breese and DeBoer 1966; Carrascosa *et al.*, 1984; Moura Nunes *et al.*, 1975).

Similar to what has been found in poxvirus virions, ASFV virions contain enzymatic activities that contribute to early events in, and activities critical for, viral replication in the cell cytoplasm, including RNA polymerase, nucleoside triphosphate phosphohydrolase, topoisomerase, mRNA capping, and protein kinase activity (Kuznar *et al.*, 1980 and 1981; Polatnick 1974; Salas *et al.*, 1981 and 1983).

Genomic heterogeneity among African ASFV isolates associated with disease outbreaks in domestic swine relative to isolates isolated from ticks has been reported (Dixon and Wilkinson, 1988; Sumption *et al.*, 1990). Subsequent molecular phylogenetic studies utilizing part of the p72 gene support some of these findings, including relative homogeneity among West African, European, and American isolates, homogeneity among certain African lineages associated with
outbreaks in domestic swine, and relative heterogeneity among isolates from southern and East Africa (Bastos et al., 2003; Lubisi et al., 2003; Wambura et al., 2006).

Nevertheless, the ASFV proteins are quite conserved across the different isolates. The central genomic core is identified as relatively conserved among different virus isolates. These include membrane and other structural proteins known to be present in the virus particle, and those that more recently have been shown to affect different stages of virion morphogenesis in the infected cell (Afonso et al., 1992; Alcamí et al., 1992 and 1993; Brookes et al., 1998b; Camacho and Viñuela 1991; López-Otin et al., 1988 and 1990; Muñoz et al., 1993; Rodríguez et al., 1994; Simon-Mateo et al., 1995; Sun et al., 1995 and 1996). Other ASFV proteins share sequence similarity to cellular proteins or enzymes, including those involved in aspects of nucleotide metabolism, DNA replication and repair, transcription, and protein modification, and those that likely account for enzymatic activities present in ASFV virions or induced in infected cells (Baylis et al., 1992, 1993a; Blasco et al., 1990; Boursnell et al., 1991; Freije et al., 1993; Hammond et al., 1992; Lu et al., 1993; Martín Hernandez and Tabares 1991; Martín et al., 1994; Rodríguez et al., 1993b; Yanez 1993; Yanez et al., 1993a, 1993b and 1993c). Several of these proteins appear to be distantly related to homologs identified in poxviruses (Baylis et al., 1993b; Blasco et al., 1990; Boursnell et al., 1991; Freije et al., 1993; Martín Hernandez and Tabares 1991; Roberts et al., 1993; Yanez et al., 1993b). Additional enzymatic components encoded in the ASFV genome include homologs of cellular ubiquitin conjugating enzyme, trans-prenyltransferase, NifS-like protein, and components of a base-excision repair pathway (Hingamp et al., 1992; Rodríguez et al., 1992). ASFV also encodes proteins predicted to mediate virus–host interaction, virulence, and mechanisms that enhance the ability of the virus to successfully replicate within the host, including homologs of cellular inhibitor of apoptosis (IAP), Bcl-2, I Kappa B (IKB) myeloid differentiation primary response antigen MyD116, lectin-like, and CD2 proteins (Borca et al., 1994b; Neilan et al., et al. 1993a; Rodríguez et al., 1993a; Sussman et al., 1992). Notably, several of these putative virulence/host range proteins, along with certain multigene family (MGF) proteins, the central variable region protein 9-RL (pB602L as annotated in BA71V), and the variable tandem repeat-containing structural protein p54 (pE183L) (Irusta et al., 1996; Rodríguez et al., 1994; Sun et al., 1995), are among the most variable among multiple field isolates.

Recently, several reports have contributed to understanding the role of several viral proteins that were previously uncharacterized or partially characterized. Some of these proteins are critical for virus replication as the E2 ubiquitin conjugation enzyme I215L (Freitas et al., 2018), the viral decapping enzyme D250R or g5R (Quintas et al., 2017), a virus histone like protein pA104R (Frouco et al., 2017), the apoptosis inducing protein A179L (Banjara et al., 2017), the virus topoisomerase II protein (Freitas et al., 2016), and the viral protein Ep152R of unknown function, except for its specific binding to host protein BAG6 (Borca et al., 2017), which has been previously described to be essential for virus replication.

The process of virus replication has also received attention in the last few years. Besides the essentiality of virus proteins described above, the critical importance of the putative cell receptor CD163 in mediating virus infection in swine macrophage cultures and in in vivo replication in swine has been addressed. Genetically edited pigs lacking CD163 did not differ from their normal counterparts in terms of susceptibility to virus infection and are fully susceptible to
ASFV (Popescu et al., 2017) clearly indicating at least an alternative pathway for virus entry to susceptible cells. In addition, the role of cellular vesicular system has been shown to be critical during virus replication (Cuesta-Geijo et al., 2012, 2016, 2017), as well as the ubiquitine proteasome system (Barrado Gil et al., 2017).

**Gaps**

Although there is only a single virus species, currently 24 genotypes have been described, with Genotype 23 and 24 just described in 2017 and 2018, respectively (Achenbach et al. 2017; Quembo et al. 2018); however, this designation is based on the sequencing of a single gene. Full genome sequence of the *p54*-gene has been confirmed as a valuable additional genotyping method for molecular epidemiological studies. Enhanced discrimination is obtained by analysis of the central variable region (CVR) within the B602L-gene, described as the most variable locus to distinguish between closely related isolates and identify virus subgroups within several of the 24 genotypes (Gallardo et al, 2009). Clearly, there are significant differences in genome size, virulence and immunogenicity (no cross-protection), but little is known about the genes responsible for virulence, host range, and viral-vector-host interactions.

**Lack of available sequences for ASFV genomes and hosts genomes of ASFV susceptible species**

Another important gap is the lack of available sequences for ASFV genomes and host genomes of ASFV susceptible species. Currently there are very few full length genome sequences of ASFV isolates deposited into the common databases, with only nineteen available at NCBI (National Center for Biotechnology Information). These strains are summarized in Table II, including their collection date, country of origin and the host they were isolated from. The very limited sequence data was obtained from six isolates that originated from ticks, ten from domestic swine and one from warthogs, and one from wild boar. The lack of diverse sequence information allows for only very limited interpretation of the differences between different isolates. The major gaps identified in the available full-length genomic sequence of ASFV isolates are as follows:

1) Isolates from different origins and hosts including domestic pigs, wild boar, warthog and ticks.
2) Naturally occurring or lab derived attenuated isolates
3) Evolution of isolates from endemic areas in regard to both time and distance.
4) Field strains from current outbreaks in Africa

Interesting information was presented in Ploufragan related to the attenuated phenotype of genotype II ASFV found in Estonia (Zani et al., 2016). This virus was re-isolated from an experimentally infected wild boar in the clinical phase of infection. This animal recovered later and was found virus negative and antibody positive by the end of the trial. Commingling of this survivor with sentinel pigs did not lead to disease transmission despite the fact that the wild boar was still positive for viral genome at the time of commingling. The virus isolate was further tested in mini-pigs, domestic pigs and European wild boar. While very mild disease was produced in the former, all wild boar died showing an acute-lethal disease course. This viral strain showed a large deletion in its 5’-end of the genome and a reorganization. Further studies are under way, but awareness should be raised to the fact that mild disease courses can occur.
Interestingly, the variant virus was found in the field only for a very short period, suggesting a disadvantage in the disease cycle. Similar attenuated viral strains have been reported from other Baltic States, warranting further studies.

The genomes of susceptible host species are an additional major gap in ASFV research. While there are fourteen individual genomes from breeds of *Sus scrofa* on NCBI, the genome sequences of the wild and domestic pigs, boar and warthogs in outbreak areas of Africa and Europe remains largely unknown. In order to conduct genomic studies as to what factors contribute to resistance of some of these breeds, a large-scale sequencing effort would have to be conducted. The major Gaps would include the species and subspecies of both domestic and wild pigs in endemic or outbreak areas, and the genomic sequences of animals that are able to survive an outbreak.

Although recent advances in next-generation sequencing have proven to be of value for both the sequencing of ASFV and host genomes, the problem still exists, largely due to the extensive cost and amount of work involved not only in sampling but also in sequencing and building these large genomes. In the case of ASFV genome sequencing, better protocols to separate the viral DNA away from the host DNA could make the sequencing effort easier and more cost effective. Without this information functional genomic studies are limited only to a particular strain being used by an individual laboratory. As this information becomes more readily available it will allow for a better prediction of the potential cross protection between isolates and virus evolution, both over time and during individual outbreaks.

**Transcriptomics of ASFV and of the host during various stages of infection**

ASFV has 150-170 ORF (open reading frames), however the majority of these ORFs are only predictions and very few have any experimental evidence on either the RNA or protein level. While it is likely that the majority of these ORFs do produce a protein product, it is possible that the expression profiles of these viral genes could vary between isolate and could differ depending on which host is infected, which could explain the varying outcome of ASFV varying from 100% mortality to sub-clinical infections. However, to date there is no published information on the RNA or protein profiles of ASFV expressed genes, even at the experimental or in vitro level.

In Ploufragan (Jaing *et al.*, 2016) presented the gene expression profile analysis of whole blood RNA from pigs infected with low and high pathogenic ASFV. RNAseq analysis identified 395 genes most differently expressed at euthanasia day in the highly pathogenic Georgia 2007 strain and 181 genes modified at 7 days post infection in the attenuated OURT88/3 group. The top 20 common genes that had the highest differential expression between both groups were genes related with macrophage markers, natural killer cell markers, chemokines and other important immune response markers.

There is a gap in knowledge for which are the receptor(s) that the virus uses to infect swine macrophages. It is possible that a number of molecules act as receptors and co-receptors at infection. One of the candidate genes CD163, a scavenger receptor which is expressed by mature macrophages and correlates with permissiveness to ASFV infection. However, using
CRISPR/Cas9 gene-edited pigs with a mutated CD163 demonstrated that the recombinant pigs lacking CD163 were still susceptible to infection with no changes observed in viral virulence, suggesting that CD163 is not the receptor for ASFV (Popescu et al., 2017). The use of a wild boar isolated stable cell line (WSL) to grow adapted ASFV from several different isolates was reported as a useful tool for virus growth in cell culture as no observed large deletions in the genome were detected with full length sequencing of these viral genomes after successive growth passages of several ASFV virus isolates. (Keil et al., 2016).

These new reports are increasing knowledge of mechanisms of infection and will help in understanding virus-induced immunity and the identification of new gene candidates for vaccination. However, new experimental data will be necessary to fully elucidate and understand how the virus interacts with the host on a cellular level.

One of the major gaps identified was that the global expression profiles of host cells infected with ASFV has not been fully determined. This information could be used to determine how the host responds to viral infection, and the molecular pathways that are both turned on or off during viral infection. These types of experiments could be used to compare the host cell response to different strains, for example to compare an attenuated ASFV strain with that of the parental virulent virus. This information could lead to a better knowledge of both naturally occurring or lab generated attenuated isolates of ASFV. Understanding this information could help in the understanding of how these viruses are attenuated. Once the host cell response is understood at a cellular level, this information could also be gathered and applied to the response in the host.

Increasing the knowledge on the transcriptomics of both ASFV and the host infected with ASFV will bring a better understanding to both strain variability in ASFV and in the varying host immune response to the virus between both virus isolates and host species.

Functional Genomics of ASFV proteins

The majority of ASFV proteins, have limited experimentally proven functions; functional genomics has been limited to mostly prediction, either by conserved protein sequences or domains in other virus families or host proteins. The lack of experimentally proven functions is a major gap in ASF research. Understanding the role for ASFV proteins during infection is critical to understanding both the pathogenesis of ASF, but also understanding how ASFV is able to avoid detection by the host immune system and cause disease. Understanding the functionality of any particular ASFV protein shouldn’t stop at functional prediction, and identification of the protein partners both viral and host for a particular protein is a major gap in ASFV research. To date there has been very little information reported for host-viral protein interactions.

Some relevant recent information was released at the GARA Gap Analysis Workshop in Ploufragan, France, referring to the previously uncharacterized ASFV Ep152R gene functionality and its interaction with cellular protein Bag6 (Borca et al., 2016). It was also reported the identification the mechanism of virus uncoating at viral entry by endocytosis and some cellular molecules that are relevant to this process (Cuesta-Geijo et al., 2016). Also, they reported the previously unidentified role of natural innate immunity mechanisms related to interferon induced proteins that are able to inhibit virus entry to the cytoplasm from the endosome called IFITM
proteins (Muñoz-Moreno et al., 2016). In addition the purification of ASFV particles and characterization of the proteome of mature extracellular ASF virions using a mass spectrometry approach was reported, and the identification of new viral and host-derived ASFV structural proteins was also presented (Kessler et al., 2016).

A clear understanding of the functionality of ASFV proteins and the role they play during infection, in particular how ASFV evades the immune response, is critical for the development of rationally designed live-attenuated vaccines. Large scale functional genomic studies represent a significant part of this gap that could be accomplished either by direct protein-protein identification methods such as yeast two-hybrid or Co-immunoprecipitation (Co-IP) followed by mass spectroscopy. Purification of viral proteins and in vitro assays to confirm their functional prediction functions would be of additional value.

Host Genomic Screens to determine virulence factors for ASFV

In light of today’s technology, in which large scale genomic screens have been accomplished for many other viruses, to date no such screens have been reported for ASFV, representing a large Gap in ASFV research. These genomic screens need swine specific reagents, for example loss of gene function screens both either by siRNA screening or CRISPR/Cas9 screening would require a library that is targeted against the swine genome. Development of these swine specific libraries would be necessary for reliable large scale in vitro genomic screens for ASFV. These screens would help gain an insight into the host pathways that are critical for ASFV replication, and could lead to the discovery of the virus cellular receptors, immune markers of infection, and the pathways involved in virus replication and virus virulence. This information would contribute to understanding virus cell tropism and thus to development of cell lines that support virus replication as well as improving understanding of virus pathogenesis.

Research needs
1) ASFV genomic sequences:
With current DNA sequencing technologies it would be relatively easy and cheap to sequence the complete genomes from 1) 1-3 isolates from each genotype, 2) a series of viruses (>10) with different virulence and 3) a series of viruses (>5) that have replicated exclusively in domestic pigs, wild pigs and ticks.

2) ASFV bioinformatics resource:
There is a need to continue the annotation and analysis of ASFV genomes. The size range of ASFV is difficult and requires specialized tools. The acquisition of more genome sequences will make the management and comparison of the gene complement even more complicated. Although there is a good amount of sequencing data available for ASFV, using current, very robust technologies, it has been possible to develop a comprehensive database, which includes full length genome sequence of large number of isolates to replace the current less meaningful genotype based classification: https://virology.uvic.ca/organisms/dsdna-viruses/asfarviridae/

3) CRISPR/Cas9 or siRNA libraries targeting swine genomes.
Development of a swine specific knockout libraries are critical for in vitro genomic screens for ASFV. Libraries targeting the swine genome would be highly valuable to perform host genomic
screens for ASFV for a wide range of experimental avenues that could lead to the discovery of potential receptors, pathways modulated to avoid immune detection or for increased virus virulence.

4) Viral Transcriptomic Studies
Genomic wide either on the RNA or Protein level data for ASFV gene expression would be relatively easy with current technologies and could provide data to determine differences in ASFV gene expression in vitro and in vivo in different hosts.

**Pathogenesis**
African swine fever virus infection of domestic swine results in several forms of the disease, ranging from highly lethal acute manifestations to subclinical depending on contributing viral and host factors (Tulman et al., 2009). In Africa, highly virulent viruses produce a broad range of responses in populations of pigs in endemic areas. At the herd or population level, infections may result in 50-100 percent of the pigs seroconverting, but showing no signs of disease, with variable proportion of the pigs dying of acute ASF. Unlike domestic swine, wild African suids infected with ASFV are generally asymptomatic with low viremia titers (Heuschele and Coggins 1969; Montgomery 1921; Plowright 1981; Thomson 1985). These features of ASF presentation and the resemblance of the clinical manifestation to other diseases in swine such as Erysipelas and Classical Swine Fever hamper syndromic surveillance in domestic swine based exclusively on clinical signs.

Infection usually occurs through the oronasal route with primary virus replication in tonsils followed by a viremia with further secondary replication of all organs of the hemolymphatic system. In the acute form of the disease, the incubation period ranges from 5 to 15 days. Affected animals exhibit fever and anorexia followed by congestion and cyanosis of the skin, increased respiratory and heart rates, nasal discharge, incoordination, vomiting and, finally, coma and death. Hemorrhage may be observed clinically in multiple forms and secretions including epistaxis, melena, hematochezia, and hematemesisis. Survival times for animals infected with African ASFV strains range from 2 to 9 days (Conceicao 1949; Creig and Plowright 1970; Haresnape et al., 1988; Mendes 1961; Thomson et al., 1979; Howey et al, 2013). Typical clinical pathological findings in acute ASF include leukopenia (Detray and Scott 1957; Edwards et al., 1985; Wardley and Wilkinson 1977), B and T cell lymphopenia (Sánchez Vizcaino et al., 1981; Wardley and Wilkinson 1980), thrombocytopenia (Anderson et al., 1987; Edwards 1983; Edwards et al., 1985), lymphocyte and mononuclear cell apoptosis (Carrasco et al., 1996; Gomez-Villamandos et al., 1995; Ora et al., 1998c; Ramiro-Ibañez et al., 1996; Salguero et al., 2004). Morphologic lesions may include hemorrhage in lymph nodes, spleen, kidneys, and respiratory and gastrointestinal tracts, congestion of skin and serosae, severe interlobular lung edema, and cavitory effusions which may range from serofibrinous to hemorrhagic. (DeKock et al., 1994; Detray 1963; Konno et al., 1972; Manso Ribeiro and Rosa Azevedo 1961; Maurer et al., 1958; Montgomery 1921; Nunes Petisca 1965; Steyn 1928 and 1932; Howey et al, 2013). The extensive necrosis in affected tissues and severe hemostatic and hemodynamic changes are likely important factors leading to death. Acute ASF also induces significant changes in acute-phase proteins (Carpintero et al., 2007; Sanchez-Cordon et al., 2007). Subacute cases last 3–4 weeks and the most prominent signs include remittent fever, loss of condition, pneumonia, dyspnea, cardiac insufficiency and swelling of the joints. While hemorrhage of lymph nodes and
other tissues may be found, it is not as prominent as in acute ASF (Moulton and Coggins 1968a). The primary cell types infected by ASFV are those belonging to the mononuclear-phagocytic system, including fixed tissue macrophages and specific lineages of reticular cells (Colgrove et al., 1969; Konno et al., 1971a and 1971b; Mebus 1988; Moulton and Coggins 1968a). Affected tissues show extensive damage after infection with highly virulent viral strains. Moderately virulent ASFV strains also appear to infect these cell types, but the degree of tissue involvement and the resulting tissue damage are much less severe. The ability of ASFV to replicate and efficiently induce marked cytopathology in macrophages in vivo in numerous porcine tissues (Howey et al., 2013) appears to be a critical factor in ASFV virulence.

Long term persistence following infection of pigs with genotype I isolates of reduced virulence has been demonstrated (Wilkinson 1984; Carrillo et al., 1994). These persistent infections have been demonstrated to be transmissible from pigs persistently infected with the low virulence genotype I NH/P68 isolate to contact pigs (Gallardo et al. 2015). Low virulence isolates can cause chronic forms of the disease, which are characterized by the absence of typical acute-phase lesions and low mortality rates, but distinct clinical signs including delayed growth, emaciation, joint swelling, skin ulcers and secondary bacterial infections are common (Sanchez-Vizciano 2015). Pigs that survive infection have been shown to carry virus in tissues or blood for long periods of time, which may contribute to virus transmission, disease persistence, sporadic outbreaks and sudden reactivation of the disease (Costard et al. 2013; Gallardo et al., 2015). Some studies in Africa have identified ASFV nucleic acid in apparently healthy pigs (Kalensi Atuhaire et al., 2013; Thomas et al., 2016) that were positive for ASFV by PCR in tissues but negative in blood by PCR and serology (Okoth et al. 2013; Abworo et al., 2017). There is limited experimental evidence for transmission from persistently infected to naïve animals, and the relevance of persistently infected animals as carriers of ASF in the field is not clear, but data on healthy infected animals keeps accumulating (Titov et al. 2017, Abworo et al., 2017, Thomas et al., 2016, Muhangi et al., 2015, Braae et al., 2015, Athuaire et al., 2013), suggesting that the virulent virus could survive for long periods of time in the recovered pigs and a recrudescence of virulence may occur at later times (Titov et al., 2017).

Persistent infection with ASFV has been reported to occur in warthogs and in domestic pigs surviving acute viral infection [DeKock et al., 1940; Detray 1957; Plowright et al., 1969]. Under experimental conditions, long-term persistent infection is the sequel to infection with ASFV (E75-L7 administered at low dose intramuscularly (im), E75-CV1 on and challenged twice with E75-L7, and E75-CV1 challenge once with E75-L7) in domestic pigs (Carrillo et al., 1994). In these animals, viral DNA was detected in the peripheral blood monocyte fraction more than 500 days post inoculation (p.i.) by PCR in intermittent periods; however, infectious virus could not be isolated from these samples and transmission was never demonstrated. Recent data using a moderately virulent isolate of different genotype during a shorter period of time (Petrov et al., 2018), do not support the establishment of a carrier status in animals surviving infection, though long term detection of viral genome in blood (for at least 90 pi) is consistent with many other reports (McVicar 1984; Mebus and Dardiri, 1980; Carrillo et al., 1994; Gallardo et al., 2015; Carvalho Ferreira et al., 2012).

In sub-Saharan Africa, ASFV is maintained in a sylvatic cycle between wild suids (warthogs) and argasid ticks of the genus Ornithodoros (Plowright et al., 1969a and 1969b; Thomson et al.,
1983; Wilkinson 1989). However, other wild pigs such as bush pigs do not inhabit burrows, and therefore would most likely spread ASFV via direct transmission, although evidence for such occurrences is limited (Jori and Bastos 2009; Jori et al. 2013). Unlike domestic swine, wild suids infected with ASFV are generally asymptomatic with low viremia titers (Heuschele and Coggins 1969; Montgomery 1921; Plowright 1981; Thomson 1985). Most adult warthogs in ASFV enzootic areas are seropositive and are likely to be persistently infected. Like warthogs, bushpigs develop subclinical infection and are more resistant to direct-contact transmission than are domestic species; however, the duration of ASFV viremia may be extended (Anderson et al., 1998). Although ASFV replication in blood leukocytes of domestic swine, warthogs, and bushpigs in vitro is similar, ASFV replication, spread, and induction of lymphocyte apoptosis in vivo is reduced in bushpigs when compared to domestic swine (Anderson et al., 1998; Oura et al., 1998a and 1998b).

There has been some characterization of the role of some of the ASFV genes in virus virulence. It is increasingly apparent that the terminal genomic regions and Multigene Family (MGF) genes play a significant role in ASFV host range. ASFV proteins involved in nucleotide and nucleic acid metabolism have been implicated in macrophage host range and similar to those in other large DNA viruses, may provide the deoxynucleotide pools favorable for efficient virus replication in specific cell types. Deletion of the dUTPase (E165R gene) and thymidine kinase (K196R gene) genes from ASFV reduces its ability to replicate in macrophages and attenuate the virus for swine, similarly correlating macrophage host range with virulence in swine (Moore et al., 1998).

Alternatively, several ASFV genes or gene regions are associated with viral pathogenesis and virulence in domestic swine but do not affect viral replication in macrophages in vitro. Two of these, UK (DP96R) and 23-NL (DP71L or l14L), are adjacently located in the genome. UK, an early protein, is quite variable between virus isolates, lacks similarity to other known proteins and deletion of UK from pathogenic ASFV, although it does not affect viral growth in macrophages in vitro, markedly attenuates the virus in swine (Zsak et al., 1998). The other gene, 23-NL, encodes NL a protein with similarity to cellular MyD116 and to the herpes simplex virus neurovirulence factor ICP34.5 (Sussman et al., 1992; Zsak et al., 1996). Deletion of NL from the ASFV E70 strain attenuates the virus in swine without affecting viral replication in macrophages in vitro.

Large deletion of six MGF360 genes and two MGF530 genes significantly reduces viral replication in macrophages (Neilan et al., 2002). Recently, it has been shown that these deletions, either naturally developed during the process of adaptation to grow in established cell lines (Krug et al., 2015), or introduced by genetic manipulations (O’Donnell et al., 2015b; Reis et al., 2016; Sanchez-Cordon et al., 2016), closely associate with decrease virus virulence in experimental infection studies in swine. Virulent isolates Georgia2007 (O’Donnell et al., 2015b) and Benin (Reis et al., 2016; Sanchez-Cordon et al., 2016) became completely attenuated and were able to induce solid protection against the challenge with the homologous virus.

In addition, a novel gene, DP148R, has been recently characterized (Reis et al., 2017). Deletion of this gene, which is clearly involved, as MGF360/530 genes, in interferon response
modulation, reduces virulence of the Benin isolate in pigs and induces protection against challenge with the homologous virus.

These studies have made significant contributions in increasing our understanding of the molecular basis of ASFV pathogenesis and the particular role of viral proteins in the outcome of the disease.

Gaps
In the course of chronic forms, the morbidity and mortality rates are lower than in acute and subacute forms of ASF, where severe inflammatory changes responsible for intense tissue injury and lymphoid depletion have been observed, inducing the death of the animals. Research to understand pathogenic mechanisms of chronic forms induced by low virulence ASFV isolates could provide useful information. The mechanisms responsible for animal survival to infection are not well understood, including the mechanisms involved in the protective immune response responsible for the appearance of carrier animals.

The use of attenuated strains obtained by genetic manipulation or by adaptation to different cell lines provides a valuable tool to study mechanisms of attenuation. Comparative analysis of host and virus behaviour using parental virulent versus their derived attenuated strains, particularly focusing the early stages of the infection, would provide critical data regarding the host and virus mechanisms causing virus attenuation. Of particular interest are the studies that may be performed using pairs of virulent/attenuated strains differing only in a single gene, eliminating noise created by different genetic backgrounds among different virus strains. Differences in patterns of virus replication, kinetics and severity in presentation of micro and macro pathology and patterns of host gene activation should be analysed in swine infected with each of the paired virus.

Significant gaps in the basic knowledge of ASFV pathology include the identification of:
1) Basic mechanisms governing animal to animal infection.
2) The analysis of different aspects in the process of host-virus interaction, particularly during early (primary) infection.
3) Molecular differences in the pathogenesis process induced by virus with different degree of virulence
4) The role of specific genomic determinant(s) in disease outcome.

Research needs
1) Basic parameters governing host to host infection, including domestic and wild swine as well as the arthropod host.
2) Study the pathogenesis of ASFV isolates with different virulence in diverse susceptible host in order to identify, and ultimately subvert the early events of infection.
3) Assess the rate of transmission of strains of ASFV of different virulence in infected-contact animal experiments.
4) Determine patterns of activation of immunologically relevant host genes particularly at early stages after infection.
5) Identify ASFV genes and genetic determinants (group of genes like multigene families) involved in host range, virulence and pathogenicity.
IMMUNOLOGY

A key hurdle in developing a safe and effective ASF vaccine has been the lack immunological information. Attempts to vaccinate animals using infected cell extracts, supernatants of infected pig peripheral blood leukocytes, purified and inactivated virions, infected glutaraldehyde-fixed macrophages, or detergent-treated infected alveolar macrophages failed to induce protective immunity (Coggins 1974; Forman et al., 1982; Kihm et al., 1987; Mebus 1988). Homologous protective immunity does develop in pigs surviving viral infection. Pigs surviving acute infection with moderately virulent or attenuated variants of ASFV develop long-term resistance to homologous, but rarely to heterologous, virus challenge (Hamdy and Dardiri 1984; Ruiz-Gonzalvo et al., 1981). Pigs immunized with live attenuated ASF viruses containing engineered deletions of specific ASFV virulence/host range genes were protected when challenged with homologous parental virus (Lewis et al., 2000; Moore et al., 1998; Zsak et al., 1996 and 1998). Humoral and cellular immunity are significant components of the protective immune response to ASF. Antibodies to ASFV are sufficient to protect pigs from lethal ASFV infection (Hamdy and Dardiri 1984; Onisk et al., 1994; Ruiz-Gonzalvo et al., 1981). Although ASFV neutralizing antibodies directed against virion proteins p30, p54, and p72 have been described (Borca et al., 1994a; Gomez-Puertas et al., 1996; Zsak et al., 1993), they are not sufficient for antibody-mediated protection (Neilan et al., 2004). CD8+ lymphocytes also appear to have a role in the protective immune response to ASFV infection (Oura et al., 2005).

ASFV, similar to other large DNA viruses, affects and modulates host immune responses. ASFV-infected macrophages mediate changes in cellular immune function, and they likely play a role in the severe apoptosis observed in lymphoid tissue (Childerstone et al., 1998; Oura et al., 1998c; Ramiro-Ibañez et al., 1996; Takamatsu et al., 1999). ASFV inhibits phorbol myristate-induced expression of proinflammatory cytokines such as TNF-α, IFN-α, and IL-8 while inducing production of TGF-β from infected macrophages (Powell et al., 1996). Conversely, increased TNF-α expression has been reported after ASFV infection in vitro and in vivo and TNF-α may play a key role in ASFV pathogenesis, including changes in vascular permeability, coagulation, and induction of apoptosis in uninfected lymphocytes (Gomez del Moral et al., 1999; Salguero et al., 2002 and 2005). Notably, ASFV strains with different virulence phenotypes differ in their ability to induce expression of proinflammatory cytokine or IFN-related genes in macrophages early in infection (Afonso et al., 2004; Gil et al., 2003; Zhang et al., 2006). The ASFV ankyrin repeat-containing protein pA238L (5EL) is the only known viral homolog of cellular IkB proteins, the cytoplasmic inhibitors of the NFκB/Rel family of cellular transcription factors, and it is thought to be important in evading host immune responses (Miskin et al., 1998; Powell et al., 1996). The activity of pA238L provides a novel mechanism for ASFV to modulate the response of host cells to infection, especially considering the role of NFκB transcriptional pathways in inducing expression of a wide range of proinflammatory and antiviral mediators and cytokines. Consistent with this role, pA238L is able to regulate expression of cyclooxygenase-2 (COX-2), TNF-α, and inducible nitric-oxide synthase (iNOS). COX-2 downregulation occurs in an NFκB-independent, but NFAT-dependent, manner (Granja et al., 2004b). Similarly, pA238L inhibits expression of iNOS, and ultimately production of nitric oxide, by a mechanism likely involving p300 transactivation. Interestingly, deletion of A238L from pathogenic ASFV does not affect viral growth in macrophages in vitro or viral pathogenesis and virulence in domestic swine (Neilan et al., 1997b). Additional ASFV-encoded proteins
modulate or interfere with host immune responses. The ASFV 8DR protein (pEP402R) is the only known viral homolog of cellular CD2, a T cell protein involved in co-regulation of cell activation (Borca et al., 1994b; Rodriguez et al., 1993a). 8DR is necessary and sufficient for mediating hemoadsorption by ASFV-infected cells (Borca et al., 1994b; Rodriguez et al., 1993a). Deletion of the 8DR gene from the ASFV genome led to decreased early virus replication and generalization of infection in swine, and 8DR suppressed cellular immune responses in vitro (Borca et al., 1998). Side by side comparative in situ hybridization tests demonstrated that deletion of CD2 homologue absolutely abolished ASF viral replication in Thymus (Borca et al. 1998). The ASFV pEP153R (8CR) protein is similar to cellular and poxviral proteins resembling C-type lectin-like proteins, including membrane-bound immunooactivation and immunoregulatory proteins CD69 and NKG2 (Neilan et al., 1999; Yanez et al., 1995). A potential role for pEP153R in immunomodulation may be subtle, however, since pEP153R does not affect viral pathogenesis or virulence in domestic swine (Neilan et al., 1999). Evidence also suggests that ASFV dramatically affects Th2/B cell responses, including upregulation of Th2 cytokines by a soluble virulence factor (p36) released from ASFV-infected monocytes and the nonspecific activation and apoptosis seen in B cell populations from ASFV-infected animals (Takamatsu et al., 1999; Vilanova et al., 1999). ASFV multigene family 360 and 530 genes play a role in modulating host innate responses. Unlike wild type virus, infection of macrophages with Pr4Δ35, a mutant virus lacking MGF360/530 genes, resulted in increased mRNA levels for several type I interferon early-response genes (Afonso et al., 2004). Analysis of IFN-α mRNA and secreted IFN-α levels at 3, 8, and 24 hours post infection (p.i.) revealed undetectable IFN-α in mock and wild type-infected macrophages but significantly increased IFN-α levels at 24 hours p.i. in Pr4Δ35-infected macrophages, indicating that MGF360/530 genes either directly or indirectly suppress a type I IFN response. This effect may account for the growth defect of Pr4Δ35 in macrophages and its attenuation in swine (Zsak et al., 2001).

In this regard, several reports support the importance of the function of MGF genes in the modulation of IFN responses, and their importance in virus virulence. The original experiments from Neilan et al., 2002, showing that deletion of MGF360/MGF530 genes reduce viral replication in macrophages, have recently been extended by others to show that these deletions also closely associate with decrease virus virulence in experimental infection studies in pigs (Krug et al., 2015; O’Donnell et al., 2015b; Reis et al., 2016; Sanchez-Cordon et al., 2016). Similarly, deletion of a recently characterized gene, DP148R, also involved in interferon response modulation, was also shown to reduce virulence of the Benin isolate in pigs (Reis et al., 2017).

Important progress has also been made in the characterization of immunogenicity of ASFV proteins in pigs. For example, several reports are now available describing cellular and antibody responses elicited by ASFV antigens individually expressed using a diversity of expressing vectors: vaccinia virus (Lopera-Madrid et al., 2017); DNA immunization (Argilaguet et al., 2012; Argilaguet et al., 2013; Lacasta el al., 2014); adenovirus (Lokhandwala et al., 2016; Lokhandwala et al., 2017); or the combination of these expression vectors (Jancovich et al., 2018). Some of these reports have gone further and also evaluated the ability of these viral proteins to induce a protective immune response in pigs (Argilaguet et al., 2012; Argilaguet et al., 2013; Lacasta el al., 2014; Jancovich et al., 2018). However, to date, most of these studies have only shown protection that does not reach values higher than 50% of the individuals under
study, indicating the need of further work in order to expand the identification of virus antigens involved in the induction of protective immune responses.

In conclusion, a significant amount of data has now been accumulated toward the immunogenic characterization of several ASFV proteins. Importantly, in some cases, these virus proteins have also been evaluated for their ability to induce a protective immune response in pigs, which is the first step on the road towards the potential development of subunit vaccines.

Gaps
Attempts to induce protective immunity using different vaccine platforms have to date failed. Homologous protective immunity does develop in pigs surviving acute infection with moderately virulent or experimentally attenuated variants of ASFV. These animals develop long-term resistance to homologous, but rarely to heterologous, virus challenge. Humoral and cellular immunity have been shown to be significant components of the protective immune response to ASF. Although ASFV neutralizing antibodies have been described to be directed against particular virus proteins, they are not sufficient for antibody-mediated protection. Additionally, CD8+ lymphocytes also appear to have a role in the protective immune response to ASFV infection. Thus, although humoral and cellular immune response are involved in contributing to the protection against the infection, the actual immune mechanism(s) mediating that protection is still unclear. Additionally, the viral protein/proteins inducing the protective immune mechanism are still largely unknown. On the other hand, ASFV proteins have been shown to affect and modulate host immune responses in vitro.

As described above, advances have been achieved in identifying and understanding the function of virus genes modulating the host response and its direct effect during the process of infection in the natural host. Additionally, important progress has been achieved in the study of the immunogenicity of many previously uncharacterized viral proteins when administered to the natural host. Some of the key gaps that remain include:

1) The identification of immune mechanism(s) mediating protection against infection in swine remains one of the major questions to be answered.
2) Advances in the identification of the virus protein(s) responsible for the induction of protective immune mechanism.
3) Understanding the actual role of virus driven host immunomodulation in the process of virus infection in swine.
4) Correlation of protection between heterologous viral strains remains unclear.

Mechanisms of protection
Currently there is a large gap in understanding the mechanisms of protection induced by experimental vaccines for ASFV. Currently several reported experimental single or double gene deletions in the ASFV genome have resulted in live attenuated vaccine candidates, however how these vaccines protect against ASF is largely unknown. There is a lack of knowledge of the specific role for individual ASFV proteins in induction of protection, beyond a basic protein functional prediction. The cellular and antibody mediated mechanisms involved in protection are also largely uncharacterized. In addition the mechanisms of virus (or experimental vaccine)
persistence is unknown. This is important to understand in order to avoid the persistence of live attenuated vaccines in the field and to understand and predict the persistence of filed isolates of reduce virulence.

The cellular immune response to ASFV or to any experimental vaccine is largely unknown, in part due to the lack of available knowledge on swine immunology. Currently it is largely unknown what specific cell types are involved in inducing an immune response or what cell types are involved in inducing long term protection to ASFV. To date there has been very little discovery of neutralizing or T-cell epitopes for ASFV. Recently p30, p54, p72 when expressed could produce neutralizing antibodies, but these antibodies did not confer protection to ASFV (Neilan et al., 2004). This suggests that we need to understand more broadly the role of antibodies in protection or disease enhancement, as there is potential for antibodies produced that are not neutralizing to be involved in disease, perhaps inhibiting the spread of the virus. It is also possible that antibody mediated enhancement of disease could occur as virus uptake into macrophages could be mediated by Fc receptors. Understanding the role for both antibodies to ASFV and the immune response to ASFV could allow us to understand the differences in both virulence between different ASFV isolates, and potentially an understanding why some wild African pigs become infected, but clinically do not exhibit any clinical signs of ASF. Understanding these mechanisms of protection will allow the generation of safer vaccines, including the possibility of creating subunit vaccines.

**Correlation of protection between heterologous viral strains**

The understanding of cross protection between heterologous viral strains is largely unknown, in part due to the lack of available genomic sequences of the different ASFV strains; thus, the diversity of ASFV is not clear. Largely, there has been very little work involving field strains in Africa, especially in current endemic areas. In Mozambique, serologically positive pigs were resistant to at least two highly virulent viruses, a genotype II and a genotype VIII virus, which are not closely related to one another, suggesting cross protection events under field conditions (Penrith et al., 2004). Possible countries identified for conducting cross protection studies include Uganda, Tanzania, Mozambique, and Kenya. In these countries, using endemic strains for experimental vaccines could allow the possibility of conducting long term vaccine studies involving a large number of animals.

Understanding the mechanisms of cross protection will allow better cross protective next generation vaccines, and the ability to predict which vaccine to use if a new emerging ASFV strain were to cause an outbreak. Understanding the specific viral proteins involved in cross protection would involve a large effort in sequencing current circulating ASFV strains, and large cross protection studies with divergent strains.

**Research needs**

1) Discovery of the immune mechanism mediating effective homologous and heterologous protection against virus infection.

2) Identification of viral genetic patterns that correlate with presence/absence of homologous versus heterologous protection.

4) Identify regulatory genes involved in pro-inflammatory cytokines and antibodies production and the assessment of their actual role in the process of virus infection/virulence in swine.

5) Explore the development of new assays based on cellular immunity for the early detection of the disease.

6) Improve our understanding of the role of multigene families in antigenic variability and evasion of immune response.

7) Identify and characterize genes related to host protection.

**VACCINES**

There is currently no commercial vaccine available for ASFV, nor has an effective commercial vaccine for ASF ever been available. A summary of experimental ASF vaccines reported in peer-reviewed scientific publications 2012-2018 is provided in Table III. Experimentally, homologous protection can be achieved by inoculation of pigs with low-virulence isolates obtained by passage in tissue culture or by deletion of genes involved in virulence, as well as low-virulence isolates from the field (Lewis *et al*., 2000; Leitao *et al*., 2001; Boinas *et al*., 2004). Usually these animals develop long-term resistance to homologous, but rarely to heterologous, virus challenge (Hamdy and Dardiri 1984; Ruiz-Gonzalvo *et al*., 1981). This lack of cross protection among different isolates constitutes an important issue to be considered in the development of ASFV vaccine candidates.

The mechanism of protection involves cell-mediated immunity, since depletion of CD8+ T cells abrogates protection (Oura *et al*., 2005; Denyer *et al*., 2006). A role for antibodies in protection had been shown since passive transfer of antibodies from immune pigs conferred partial protection to lethal challenge (Onisk *et al*., 1994). In experiments using recombinant proteins, partial protection was achieved using a combination of two proteins, p54 and p30, as well as with recombinant CD2-like protein (Ruiz-Gonzalvo *et al*., 1996; Gomez-Puertas *et al*., 1998). However, some of these results could not be repeated by others using highly virulent ASFV isolates (Neilan *et al*., 2004). The failure to achieve complete protection in these experiments may be because of the delivery method of the antigens and/or because more or different antigens are required to confer protection. Alternatively, it is possible that full protection can only be achieved by using live-attenuated replication competent ASF viruses as vaccines.

Pigs immunized with live attenuated ASF viruses containing engineered deletions of specific ASFV virulence/host range genes (for review see Dixon *et al*., 2008 and Tulman *et al*., 2009) were protected when challenged with homologous parental virus (Lewis *et al*., 2000; Moore *et al*., 1998; Zsak *et al*., 1996 and 1998). This preliminary work, mostly produced using historical virus strains, has been recently extended to virus isolates with current epidemiological significance. In addition, novel genes have now been identified as additional targets for deletions leading to virus attenuation. For example, deletion of 9GL, previously described with the Malawi isolate (Lewis *et al*., 2000), was deleted in the Georgia 2007 isolate (O’Donnell *et al*., 2015a), resulting in virus attenuation and demonstrated use as an experimental vaccine to protect against homologous challenge. Other genetic manipulations including deletion of a group of MGF genes either in the Georgia 2007 isolate (O’Donnell *et al*., 2015b), or Benin (Sanchez-Cordon *et al*., 2018; Reis *et al*., 2016), or the previously uncharacterized DP148R gene...
(Reis et al., 2017) attenuated the parental virus and protected against challenge with the virulent homologous virus.

Interestingly, for the first time, complex genetic manipulations with multiple gene deletions in the same virus were introduced in the Georgia 2007 isolate. Some of these attempts were initially unsuccessful, resulting in profound attenuation but failing in inducing a protective immune response (O’Donnell et al., 2016a; Abrams et al., 2013). Conversely, in other cases, combinations of gene deletions successfully increased vaccine safety and immunogenicity, as in the case of a Georgia 2007 mutant harboring deletions of both the 9GL and UK genes (O’Donnell et al., 2016b).

One concern about the use of ASFV vaccines is the potential genetic diversity of strains circulating within the same geographical area. Although anecdotal information exists suggesting the existence of cross-protection between viruses belonging to different genotypes, it was not until recently that this has been experimentally demonstrated. Deletion of CD2-like gene from the virulent Badajoz71 isolate produced an attenuated virus that induced protection to the homologous parental virus but also to the heterologous Spain75 and Armenia2010 isolates (Monteagudo et al., 2017). Interestingly, this particular virus possesses the unique characteristic of growing in an established cell line, which is paramount for a potential vaccine strain that will need to grow at high titers for vaccine production. Therefore, it may be possible to develop vaccines that can cross-protect against infection with several genotypes.

Identification and characterization of novel ASFV genes involved in virulence and in evasion of the host's immune response is still needed to facilitate and improve the development of rationally attenuated vaccines through sequential deletion/modifications of these genes. Although further research is required, it appears that development of effective vaccines is now more realistic than just a few years ago.

Alternative approaches investigating subunit vaccines based on the expression of protective antigens have not significantly progressed due to the lack of investigative work to identify viral antigens inducing protection. The recent development of high-throughput methods for constructing recombinant viral vectors opens a route for global analysis of the protective potential of all ASFV-expressed genes. In this regard, several reports studied the cellular and antibody response elicited by ASFV antigens individually expressed using a diversity of expressing vectors. Thus, vaccinia (Lopera-Madrid et al., 2017), DNA immunization (Argilaguet et al., 2012; Argilaguet et al., 2013; Lacasta et al., 2014), adenovirus (Lokhandwala et al., 2016; Lokhandwala et al., 2017) or their combination (Jancovich et al., 2018) have been used to immunize pigs with several different viral proteins that were selected using different criteria. Some of the reports are restricted to the characterization of the immune response elicited by each of the virus antigens expressed in the different vectors (Lokhandwala et al., 2016; Lopera-Madrid et al., 2017; Lokhandwala et al., 2017), without assessing the protective effect of immunization against challenge with virulent virus in pigs. In those reports where challenge studies were included (Argilaguet et al., 2012; Argilaguet et al., 2013; Lacasta et al., 2014; Jancovich et al., 2018), protection values have not reach higher than 50% of the individual animals under study. These results indicate that further work is needed in order to expand the identification of virus antigens involved in the induction of protective immune response. Future success using subunit vaccine platforms may require optimization of the immunization protocols,
including the selection of an effective vaccine vector. Importantly, it should be mentioned that it has been reported that successive immunization using vaccinia and adenovirus as vectors expressing eight undisclosed specific virus proteins protected 100% of immunized pigs from the challenge with the virulent Benin isolate (Netherton et al., 2018). This constitutes so far the only report presenting an ASFV subunit vaccine with total protective efficacy.

**Gaps**

Although live attenuated viral vaccines appear to be the most promising, one major concern is their safety. What is considered a safe vaccine could depend on the area it is going to be deployed; for example, deploying a vaccine with an identical backbone to ASFV that is circulating in an endemic area, or during an outbreak situation, is very different than deploying a vaccine in an uninfected area. Currently there has been no vaccine with a marker for differentiation of infected from vaccinated animals (DIVA).

Currently there is no validated cell line to support vaccine production, leading to another significant gap in ASFV vaccine research. Without a validated cell line, commercialization of an ASFV vaccine will not be possible. The only reported cells that supports a live attenuated vaccine are primary swine macrophages, which are commercially unfeasible to use for large scale vaccine production.

Some of the key research gaps that impede the discovery of safe and effective ASF vaccines, and in particular, vaccines that have been engineered for the purpose of control and eradication, include:

1) Determinants of ASFV virulence have yet to be identified and fully characterized, thereby limiting the development of rationally attenuated vaccine strains.
2) An immortalized cell line for ASFV vaccine production.
3) ASFV gene products that can induce a protective immune response to engineer subunit vaccines
4) Mechanisms of protective immunity.
5) Antigenic diversity between different ASFV strains and its impact on vaccine cross protection against heterologous strains.
6) Identification of antigenic markers to engineer a vaccine with negative markers to differentiate infected from vaccinated animals (DIVA).

**Research needs**

1) ASFV virology and functional genomics studies to identify targets that will inform vaccine discovery research, including novel determinants of virulence in the ASFV genome, antigenic targets required for immunity, and mechanisms of immune evasion.
2) Determine safety characteristics associated with experimental live attenuated vaccines.
3) Development of a stable cell line for vaccine production that is capable of robust ASFV growth and scalable to commercialized vaccine production.
4) Engineer additional gene-deleted recombinant ASFV as potential vaccine candidates, including addition of DIVA markers.
**DIAGNOSIS**

A wide variety of laboratory techniques are available either for ASF virus and antibody detection, and a combination of both is the recommended approach for detecting ASFV. It is important to point out that ASF presents three significant advantages for detection: i) viremia begins usually at 2-3 dpi, and it is maintained for several weeks; ii) specific antibodies appear detectable in blood from the 8-15th day post infection at high levels and persist for long periods of time, even years; iii) since there is not a vaccine available, specific antibodies (if they appear before the animal dies) are a very good marker of infection. However, oral and intramuscular experimental infections of piglets, juveniles and adult wild boar with moderately virulent isolates resulted in acute forms of ASF with 100% lethality within less than 12 days, with no detectable antibody response in serum or effective transmission to domestic contact pigs and wild boars (Gabriel et al., 2011; Blome et al., 2012). Under experimental conditions, older pigs appear to have better survival than younger pigs after infection with a moderately virulent isolate of ASFV, regardless of the inoculation dose (Post et al., 2017).

The persistence the specific ASF-IgG antibodies for long periods of time in infected pigs provide the primary strategy to detect the sub-acute and chronic forms of ASF, which is essential for ASF eradication programs. Several techniques have been adapted to ASF antibody detection, but the most common, practical and inexpensive test normally used are enzyme-linked-imunosorbent assay (ELISA), and as confirmatory tests: Immunoblotting assay (IB); Indirect immunofluorescence antibody test (IFA); and the Immunoperoxidase Test (IPT). The samples that should be collected for ASF laboratory diagnosis are: whole blood, tonsil scrapings and/or tonsil swabs from suspect live animals alive, and lymph nodes, kidney, spleen, lung, blood and serum from dead pigs. Tissues are used for virus isolation (HA test), viral antigen detection (DIF test), and DNA viral detection (PCR test), while blood, tonsil scrapings and tonsil swabs are only used for virus isolation and DNA viral detection. Serum is used for antibody detection by IFA, ELISA or IB. Tissue exudates can be used for viral detection by PCR and for antibody detection by the serological tests listed above.

The most commonly used techniques for virus detection and identification are haemadsorption (HA), direct immunofluorescence (DIF), and since 2000, the molecular detection of ASF virus by PCR. While HA and DIF tests are not commercially available, several qPCRs are now on the market and licensed in European countries (e.g., there are five licensed kits for ASFV detection in Germany from international companies and two further tests are currently in the process of being validated). It has been shown that the tests are very robust, specific and sensitive. An example is a PCR that includes all reagents dried down, as well as a rehydration buffer and a positive control (Zsak et al., 2005). An internal control is an important prerequisite for reliable testing.

**Virus Detection Techniques**

**Virus detection and isolation.**

The hemadsorption test (HA) is definitive for ASF virus identification because of its sensitivity and specificity. HA is based on the hemadsorption characteristics that most of the ASF virus
isolates induce when pig macrophages are infected in the presence of the porcine erythrocytes. A characteristic rosette around the infected macrophages develops before the cytopathic effect appears. It is important to point out that it has been observed that a small number of field strains show only cytopathic effect without producing the hemadsorption phenomenon. These strains are identified using PCR and/or DIF test on the sediments of these cell cultures.

**ASF-DNA detection.**

Since 2000, laboratory PCR tests, based on conventional and real-time procedures, have been developed and some of them have already been validated (OIE, 2000; Agüero et al., 2003; King et al., 2003; Zsak et al., 2005). These techniques use primer pairs selected from a highly conserved region of the viral DNA, within the VP72 genome region, detecting a wide range of ASF isolates belonging to all the known virus genotypes. It is an excellent and relatively rapid technique to be included in epidemiology surveillance and diagnosis of ASF. There are also fully validated commercial kits and in-house protocols targeting alternative genome regions (useful to exclude amplicon contaminations). Among the commercially available kits licensed in at least one country are: INgene q PPA (Ingenasa), virotype ASFV (Indikal Bioscience), ID Gene ASF Duplex (IDvet), and RealPCR ASFV (IDEXX). Comparative tests have been performed at the level of the EU Reference Laboratory as well as some National Reference Laboratories and results should be published soon.

**Direct immunofluorescence (DIF).**

The DIF assay is based on the demonstration of viral antigen on impression smears or frozen tissues section with an immunoglobulin conjugated against ASF virus. It is a very fast (one hour) and economic test with high sensitivity to the acute ASF form. For subacute or chronic forms, DIF test presents a sensitivity of only 40 %. This decrease in sensitivity seems to be related to the formation of antigen-antibody complexes, which do not allow the reaction with the ASF conjugate.

Additionally, there is a unique commercial ELISA viral antigen detection test, the Ag-ELISA. Both antigen detection techniques DIF and Ag-ELISA exhibit a very low sensitivity in case of chronic forms of the disease, while antigen-antibody complex are present. These techniques are only recommended for the diagnosis of acute forms of the disease. The antigen detection techniques are not recommended in case of chronic forms of the disease, in endemic areas, or for an individual diagnosis of the disease.

**Additional Tests.**

In recent years a number of diagnostic platforms have been adapted to ASF diagnosis, most of them based on DNA detection, either as part of multiplexed techniques (Lung et al., 2018, Xiao et al., 2018, Erickson et al., 2018, Hu et al., 2015, Shi et al., 2016, Sastre et al., 2016) or single detection, which includes portable PCR systems (Liu et al., 2017), lateral flow devices for antigen detection (Sastre et al., 2016), and new platforms such as use of biosensors (Mujibi et al., 2018), the droplet digital PCR ddPCR (Wu et al., 2018), the recombinase polymerase amplification, RPA (Wang et al., 2017), the Polymerase cross-linking spiral reaction, PCLSR (Wozniakowski et al., 2017), the isothermal cross priming amplification CPA (Fraczyk et al., 2018).
some of them with times as short as 10 minutes for the result, and sensitivity and specificity as high as the OIE recommended ULP-PCR.

**Antibody Detection Techniques**

**Antibody ELISA.**

This is the most useful method for large-scale serological studies. At present, at least three commercial ELISAs are in routine use (from Ingenasa, Svanova, and IDVet). Recently, another competitive ELISA was validated and found to give reliable results (IDVet, based on the p32 protein). Other ELISAs are in house or in development and validation process, and all have their strengths and weaknesses, which should be considered when testing samples of doubtful or bad quality. These tests are based on the detection of ASF antibodies bound to the viral proteins, which are attached to a solid phase by addition of protein A-conjugated with an enzyme that produces a visible colour reaction when it reacts with the appropriate substrate. A commercial Antibody ELISA is available (INgezim PPA Compact Ingenasa), and it has been validated by the Central Reference Laboratory (CRL), Spain. The procedure of an “in house” OIE ELISA as well as a standardized/validated soluble antigen for the OIE ELISA test can also be provided by CRL upon request.

**Immunoblotting assay (IB).**

This is a highly specific, sensitive and easy to interpret technique which is successfully used as an alternative method to IFA recommended as a confirmatory test of the positive or doubtful results by ELISA. There is no commercial IB Kit available, and standardized/validated IB antigen strips should be prepared by the own laboratory. It could be provided by CRL previous a request. However, due to the complexity of the IB antigen-strip production, the annual amount of it is limited.

**Indirect immunofluorescence antibody test (IFA).**

The IFA test is a fast technique with high sensitivity and specificity for the detection of ASF antibodies from either sera or tissue exudates. It is based on the detection of ASF antibodies that bind to a monolayer of cell lines (Vero cells MS) infected with an adapted ASF virus. The antibody-antigen reaction is detected by a labelled fluorescein A-protein.

**Immuno Peroxidase Test (IPT).** The IPT is an immune-cytochemistry technique on fixed infected cells to determine the antibody-antigen complex formation through the action of the peroxidase enzyme. In this procedure, Vero or MS cells are infected with ASFV adapted isolates to these cell cultures. The infected cells are fixed and are used as antigens to determine the presence of the specific antibodies against ASF in serum samples (Gallardo et al., 2015).

**Pen-side Tests.** Recently, Cappai et al., (2017) reported on the use and validation of a commercial serological pen-side test in Sardinia, Italy. The implemented test is a lateral flow device (LFD) that is produced by Ingenasa (INgezim PPA CROM). The study on hunted wild boar showed a sensitivity of 82 % and a specificity of 96 % under field conditions (better
performance under laboratory conditions). It was demonstrated that the use of pen-side tests was less expensive and laborious, while still providing expedited results. Thus, these tests could be considered under certain conditions.

The use of a combination of virological detection techniques (PCR test is recommended since Ag detection techniques such as DIF and antigen ELISA show very limited sensitivity in chronic cases) simultaneously with the use of serological test (ELISA, and confirmation of positives and doubtful results by IPT/IFA or IB), makes possible to detect all ASF epidemiology situations (acute, subacute and chronic) in very short time with accuracy and confidence.

The characterisation of ASFV isolates is performed by standardised protocol established at the international level and by the EU Regional Laboratory by genotyping. The genotyping strategy involve sequencing of three independent regions on ASFV genome; i) the C-terminal end of the gene encoding the VP72; ii) the full-gene sequencing of the VP54; and iii) the variable region within ASFV genome named CVR (central variable region) marked by the presence of tandem repeat sequences (TRS). The partial VP72 and full-length sequencing of VP54 places ASFV isolates into major subgroups prior to CVR analysis to resolve the intra-genotypic relationships of viruses causing ASF outbreaks. This method has provided additional information about strains of viruses circulating in Europe, America and Africa over a 45-year period. Furthermore, these methods have allowed determination of the genetic relationships and origin of viruses responsible for disease outbreaks occurred in the last years in Europe (Italy and Caucasus countries) and Africa.

**Recent Advances in the Development of ASF Diagnosis**

**Advances in pathogen detection.**

Recently, a study was undertaken to compare the available diagnostic test systems in the framework of the current outbreak in Eastern Europe (Gallardo *et al.*, 2015). In this study, the Universal Probe Library (UPL) PCR (Fernandez-Pinero *et al.*, 2013; Gallardo *et al.*, 2015) was the most sensitive method followed by the OIE prescribed real-time PCR (King *et al.*, 2003) and the conventional PCR. In general, agreement among the methods was fair to good (94% between UPL and real-time PCR; 88% between UPL and conventional PCR). The commercial antigen ELISA (INgezim PPA DAS K2; Ingenasa) showed a sensitivity of roughly 77%.

Isothermal amplification methods can aid diagnosis under basic laboratory or even field settings and have been investigated over the last years. Among the isothermal methods that have been tried for ASFV is cross-priming amplification (targeting the p72 gene). Fraczyk *et al.*, (2016) could demonstrate that the method was as sensitive as the UPL PCR, at least under the chosen conditions. Quite similar results were obtained for a loop-mediated isothermal amplification (LAMP) assay targeting the topoisomerase II gene. Apart from standard settings, visualization through the use of dual-labelled biotin and fluorescein amplicons on lateral flow devices was demonstrated (James *et al.*, 2010). Apart from other isothermal methods such as RPA, different field-applicable PCR machines have been tested over the last years. However, these methods need further assessment.
**Advances in antibody detection.**

For ASF antibody detection, five serological methods were recently tested, including three commercial ELISAs (from Ingenasa, IDVet, and Boehringer Ingelheim Svanova), the OIE-ELISA, and the confirmatory immunoperoxidase test (IPT). The IPT was shown to be the most sensitive assay that also allowed testing of tissue exudates (Gallardo *et al*., 2015). The IPT was able to detect ASF antibodies at an earlier point in the serological response, when few antibodies were present.

Generally, knowledge was gained and collated on suitable antigens and their expression for serodiagnosis of ASF. Evaluation of the available data also revealed strengths and weaknesses in terms of broad range of detection (Perez-Filgueira *et al*., 2006; Cubillos *et al*., 2013). For the African setting, it was demonstrated that recombinant p30 of Morara/Georgia was able to mirror the overall situation. These data fed (see Svanovir ELISA and IDScreen) and will feed into new test developments towards early and reliable detection of ASF antibodies. At present at least three commercial ELISAs are in routine use (from Ingenasa, Svanova, and IDVet), and others are under development and validation. All these tests have different strengths and weaknesses, especially when it comes to testing of bad quality wild boar sera. The results were shown to vary among laboratories.

**Recent developments in pen-side tests and alternative sampling and testing schemes.**

Apart from the single LFD for antibody detection to ASF, multiplexing has been reported with CSF, which would facilitate surveillance for both diseases (INgezim ASFV-CSFV-CROMAb) (Sastre *et al*., 2016a).

Data were presented on the last ASF-STOP meeting in Pulawy, that lateral flow devices could also be used in combination with blood swabs (Carlson *et al*., submitted).

A LFD for the detection of viral antigen has been described (INgezim ASFV-CROM) (Sastre *et al*., 2016b). The assay showed a sensitivity that is comparable with antigen ELISA. Generally, a viral load of $>10^4$ HAU would be detectable. Thus, sick animals or animals that died from ASF should be positive (in the majority of cases). In combination with other methods, this tool could add to a swift detection in remote or otherwise problematic areas (e.g. carcasses of wild boar that cannot be transported) but has, as detailed above, very limited sensitivity.

Non-invasive sampling strategies could mean an optimization for wildlife surveillance by circumventing the necessity of fitness-biased hunting/capture sampling schemes that can in the worst case even further disperse the virus. Recently, different approaches for the in-life sampling have been evaluated both under experimental and field conditions.

One option for a non-invasive approach could be the collection of faeces from the wild boar habitat. Along these lines, de Carvalho Ferreira *et al*., (2014) tested the suitability of fecal samples. They demonstrated that, in comparison with virus detection in blood, virus can be detected in faeces 50-80% of the time. For the subacute/chronic phase, this percentage decreases below 10%. Despite this rather variable detection in the course of the infection, ASFV DNA was
proven to be rather stable in faeces (half-life of more than two years at 12°C or ~15 days at 30°C, respectively) and thus, testing of faeces could supplement the tool box of monitoring methods. Apart from genome detection, it was recently shown that faeces could also be suitable for ASFV specific antibody detection (Nieto-Pelegrín et al., 2015).

Another option is the use of (bait) ropes for the collection of oral fluid. Oral fluids were shown to be suitable for antibody detection (Mur et al., 2013; Giménez-Lirola et al., 2016) and genome detection (Grau et al., 2015).

With regard to bait ropes, published studies cover mainly CSF (Mouchantat et al., 2014; Dietze et al., 2017) and FMD (Mouchantat et al., 2014), but similar approaches have been followed for ASF under both field and laboratory conditions. In Russia, ropes were left at feeding places and wild boar were shown to chew on the ropes.

Braae et al., (2013) investigated the use of FTA cards for blood collection and subsequent testing by qPCR under field conditions in Tanzania. Detection of viral DNA was demonstrated in a subset of clinically healthy animals and the principle was confirmed under laboratory settings.

These results are in line with the work published by Randriamparany et al., (2016) and Michaud et al., (2007). Here, ASFV diagnosis (and characterization) was successfully performed from dried-blood filter papers (experimental and field samples) over extended periods of time. Especially under tropical conditions, these approaches ensure suitability and stability for downstream applications without a cold chain and sophisticated transport. Randriamparany et al., (2016) could additionally demonstrate the suitability for antibody detection. In detail, the study showed that real-time UPL PCR from filter papers is as sensitive as conventional testing by virus isolation and conventional PCR, and ELISA from filter papers was comparable with the same assay from serum. No problems with specificity were encountered.

Along the same lines as the above mentioned FTA cards and filter papers, Petrov et al. (2014) could show that dry blood swabs (in general using different cotton, foam or tissue swabs) can be a valuable, stable and easy-to-handle method to test carcasses for ASFV (and CSFV) genomes. The advantage is that the swab is already combined with a shipment-suitable receptacle, and no direct contact or further equipment is needed. In the reported studies, so-called Genotubes (Thermofisher) were the optimum in terms of handling and stability. In subsequent studies, the suitability of these swabs for ASFV antibody detection by ELISA (in the protocol meant for filter paper punches) was demonstrated in a proof-of-concept study (Blome et al., 2014).

Recently, these initial data were supplemented by a broader validation study that also included the combination with antibody lateral flow devices (Carlson et al., submitted). The mentioned validation study showed the following performance characteristics for the Genotube based samples (when compared to routine diagnostic sample matrices and tests): qPCR 98.8% sensitivity [CI 93.4, 100.0] and 98.1% specificity [CI 90.1, 100.0] under laboratory conditions (85.7% [CI 71.5, 99.6] with stored field samples), and for serology by ELISA 93.1% sensitivity [CI 83.3, 98.1] and 100% specificity [CI 95.9, 100.0]. Good agreement was found when using the above mentioned antibody LFDs from Ingenasa. This concept is particularly interesting as it was shown that it had almost no problems with bad sample quality.
For pathogenesis and immune response studies (correlates of protection and virus distribution in vaccination/challenge trial) but also diagnosis from necropsies, an optimized in situ hybridization protocol for the detection of African swine fever virus (ASFV) DNA in formalin-fixed, paraffin-embedded tissues using digoxigenin-labeled probes has been described by Ballester et al., (2015).

Genotyping

To better understand the molecular epidemiology of the recent outbreaks, additional genome markers are under investigation. Among them are different intergenetic regions. Next-generation sequencing could be aided by enrichment through targeted sequence capture technology (Fernández Pinero, unpublished).

Conclusion

In conclusion, our tool box of diagnostic tests has grown considerably over the past years but there is still a need for harmonization, situation-adapted diagnostic workflows, and general knowledge of disease biology that helps us in further adjusting our methodologies. Optimized and harmonized workflows are needed for next-generation sequencing. However, it is important to note that in the last years the field of diagnostics has expanded into the search for new models of detection. Not only for the use of current techniques in new types of samples like feces (de Carvalho Ferreira et al., 2014; Nieto-Pelegrin et al., 2015), FTA cards (Braae et al., 2013), dry blood swabs (Petrov et al., 2014; Blome et al., 2014), and oral fluids (Mur et al., 2013; Grau et al., 2015; Gimenez-Lirola et al., 2016), but also searching for new models as air samples (de Carvalho Ferreira et al., 2013) and feed (Dee et al., 2018). This line of expansion will help to reach a more environmental and less invasive diagnostic as the industry desires.

Gaps

ASF is usually suspected based on clinical signs, but clinical evidence is usually nonspecific and would be difficult to differentiate from other diseases of swine, including Classical Swine Fever, Erysipelias, Salmonellosis, Eperythrozoonosis, Pasteurellosis, Pseudorabies, thrombocytopenic purpura, warfarin poisoning, and heavy metal toxicity. Regional labs in endemic countries lack the infrastructure and/or expertise for reliable diagnostic services. Some of the existing regional laboratories in Africa have limited capacity and most of them use the fluorescent tests and not real time RT-PCR.

The overarching gaps for diagnostics are:

1) There is a lack of commercial tests for large scale and confirmatory diagnostics
2) Validation of serological and virological tests for different epidemiological situations (e.g., low versus virulent ASFV strains).
3) Need to perform biological characterization and determine serotypes and pathotypes of current ASF strains that will provide the knowledge to extrapolate such characteristics using in vitro tests in the laboratory
4) In order to replace laborious and homogeneous primary cultures for virus isolation, cell cultures need to be found that support ASFV replication
5) The global ASF situation has to be considered when developing diagnostic assays. Tailored approaches could be an option for some scenarios.
6) For an early detection of the disease by serological methods, ELISA systems should be improved including the possible use of alternative sample matrices.
7) To understand the genetic diversity, studies targeting the sylvatic cycle hosts in Africa should be undertaken.
8) Pen-side tests and other field-deployable diagnostic tests need further investigation.
9) There is an urgent need to increase the knowledge of the survivor pigs from the clinical and ASF diagnosis point of view.
10) New phylogenetic markers associated with pathogenicity should be looked at.
11) Field validation of new assays is needed considering fitness-for-purpose and the overall situation.
12) There is a need to intensify training and follow-up activities for international harmonization of diagnostic tests.

Research needs
1) Identify/develop cell lines that replace primary cultures for improved virus isolation techniques.
2) Full validation of novel or modified ELISA tests for detection of antibodies in alternative sample types (e.g., blood, exudate’s tissues, oral fluids, meat juice, filter papers, etc.).
3) Improved stability of reagents in commercial diagnostic kits (molecular virological and serological assays) regarding shipment and expiration issues. This could be overcome by exploring different strategies such as gelification lyophilization and others.
4) Automation and standardization of viral genome sequencing for subtyping ASFV strains.
5) Expanded field validation of novel assays, taking into consideration the worldwide scenarios.
6) Development and evaluation of non-invasive sampling methodologies in wild suids.
7) Validate available penside diagnostic tools to enhance detection and improve surveillance in wild life in Africa.
8) Development, evaluation and field validation of commercial confirmatory serological tests.
9) Standardization and validation of ELISA tests to detect antibodies against *Ornithodoros* tick saliva antigens in bitten animals.
10) Improved knowledge of the role of the survivor pigs as potential shedders by the use of appropriated diagnostic serological and virological tests for identification/detection of these animals.
11) Study the effects and detection of low virulent isolates and persistent infections.

**Epidemiology**
African swine fever was first reported in Africa in 1909 following the introduction of European domestic pigs in Kenya. It was characterized at the time as an acute hemorrhagic disease with mortality rates of 100 percent in domestic pigs (Montgomery *et al.* 1921). It was subsequently recognized that ASF had been present in southern and eastern Africa all along in wild suids (Penrith *et al.*, 2013). Africa has remained endemic and continues to experience a significant number of ASF outbreaks annually (see Table I). Newly infected countries in Africa rapidly
become endemically infected; e.g., The Central African Republic, Chad, Ethiopia and a number of countries in West Africa (Achenbach et al., 2016; Brown et al., 2018).

The first spread of ASF outside Africa was in Portugal in 1957 as a result of waste from airline flights being fed to pigs near Lisbon airport (Costard et al., 2009; Gallardo et al., 2015). Similar means of ASFV introduction were reported for the outbreak in Brazil in 1978 (Lyra 2006). All ASF introductions outside Africa were successfully eradicated, with the exception of the infection on the Island of Sardinia, Italy. However, in June 2007, an ASF outbreak was notified to the OIE in the Caucasus region by the Republic of Georgia, presumably caused by feeding pigs with ASFV contaminated pork brought in on ships from Africa (Rowlands et al., 2008). Since then, 16 new countries have reported ASF outbreaks, including Russia, Eastern Europe, Baltic countries (Wozniakowski et al., 2016; Nurmoja et al., 2017), Bulgaria, Romania, Hungary, Czech Republic, Poland, Belgium, and on August 2018, the first report of an ASF outbreak was reported by China (see Table I).

The epidemiology of ASF may vary substantially between affected countries, regions and continents. Two types of transmission cycles have been defined for ASF based mainly on the mode of transmission of the virus among different pig populations: a domestic pig cycle and sylvatic-wild pig cycle (Costard et al., 2009). The presence/absence of arthropod vectors (i.e., tick species) in the affected area will impact the spread and maintenance of the virus in the environment (Plowright et al., 1994). In sub-Saharan Africa, ASFV is maintained in a sylvatic cycle between warthogs and ticks of the genus Ornithodoros. In endemic areas of Africa, infected ticks and warthogs are the source of virus responsible for disease outbreaks in domestic swine. Once established, virus is efficiently contact-transmitted between domestic swine (for review: Tulman et al., 2009). Infection through direct contact between domestic pigs and warthogs has not been observed (Costard et al., 2009). Thus, ASF may show unique regional patterns of presentation, associated with unique set of risk factors that should be assessed to establish proper surveillance and control strategies.

Twenty-four different p72 genotypes have been identified among virus isolates from sub-Saharan African countries. However, the use of p72 for genotyping only provides an initial characterisation and does not directly provide data on cross immunity between the genotypes or their virulence. Outside the African continent, only isolates belonging to the West African p72 genotype I, had been detected. However, the Georgian 2007 outbreak, and all subsequent ASF outbreaks in the Caucasus region were attributed to a new isolate, related to p72 genotype II, circulating in South Eastern Africa since 1989. Since then, ASF has spread to neighbouring countries of Armenia, Azerbaijan and the Russian Federation, all the way into Central and Western Europe, and the most recent intrusion declared in China, which has the largest pig population in the world. The 2018 outbreak in Asia confirmed that the threat of ASF spreading to countries outside the African continent is high and is potentially devastating to the global pig industry.

Although the importance of ASF genotypes in the biology of the virus is not well understood, it has contributed to our knowledge of the distribution and evolution of ASFV. It will be important to continue to assess ASF strains in endemic region, as demonstrated in recent reports that have
identified new genotypes in Mozambique (Quembo et al., 2017), and Ethiopia (Achenbach et al., 2017).

Based on currently available data, it is possible to delineate the following global distribution of ASFV types:

- West Africa (Genotype I)
- East and Central Africa (all genotypes known)
- Sardinia (Genotype I)
- Caucasus, Russia, Europe (Genotype II)
- China (Genotype II)

**Gaps**

There is a continuing need for knowledge on the molecular epidemiology of ASFV isolates mainly in relation to wild populations and ticks. The PCR based genotyping might be a tool in endemic areas like sub-Saharan Africa; however, in the event of an outbreak in new geographical areas, the single most important task is to complete the sequencing of the viral genome. This will provide essential information not only about the potential origin of the virus but possible homologies to other strains.

**Research needs**

1) Continuing molecular epidemiology studies to monitor both captive and wild suid populations as well as soft tick distribution is essential to effectively address the ASFV problem in endemic areas. These studies are also of great importance for preventive and surveillance programs.
2) The development of ELISA for the detection of tick presence.
3) Need to intensify virus detection, isolation and characterization from sylvatic cycle hosts in Africa for genotyping purposes.
4) Ongoing biological and molecular characterization of currently circulating isolates in Africa and Europe.
5) To identify and apply new phylogenetic markers associated with virus virulence to understand virus evolution in endemic areas.
6) To better understand the socioeconomics of the disease and pig and pork value chains, particularly those related to low biosecurity settings.
7) To better understand the costs (direct and indirect) of ASF, both in epidemic and endemic situations
8) To identify better management tools to control the disease in wild boar.
9) To better understand the role played by the environmental contamination and blood sucking insects in the disease cycle.
10) The epidemiology of ASF in emergency control programs needs to be assessed and modelled on the level of the individual pig, the herd, and the demographics of the region (low versus high density pig populations).
11) Risk assessments need to be performed with regard to control or spread of ASFV.
**SURVEILLANCE**

The clinical presentation of ASF in domestic pigs depends on the virulence of circulating virus. Infection of domestic swine results in several forms of the disease, ranging from highly lethal acute manifestations to subclinical depending on contributing viral and host factors (Tulman et al., 2009).

Unlike domestic swine, wild African suids infected with ASFV are generally asymptomatic with low viremia titers (Heuschele and Coggins 1969; Montgomery 1921; Plowright 1981; Thomson 1985). These features of ASF presentation and the resemblance of the clinical manifestation to other diseases of swine hamper surveillance based exclusively on clinical signs. Based on the complexity of the epidemiology of ASF and multiple clinical manifestation of the disease it is necessary to develop surveillance activities based on diagnostic testing.

It is worth mentioning that none of the non-invasive methods proposed for pigs or wild boars would be effective for detection of virus because they do not shed virus. If they would chew ropes it might be possible to detect antibodies. The main thing is that burrow ticks can be used for surveillance in warthogs although a lot have to be tested before a negative result would be considered reliable (Personal communication, Marie Louise Penrith).

**Gaps**

1) Surveillance is the most important countermeasure to be able to eliminate the disease at the source through early detection and containment of a disease outbreak. However, different surveillance strategies are required to detect the different clinical manifestations resulting from ASFV infections. For acute infection, surveillance activities can be based on clinical signs; however, for mild cases or chronic infections, where recognition of ASF symptoms is less likely, surveillance activities must be based on diagnostic testing to supplement surveillance based on clinical signs.
2) Passive surveillance is often the only economically viable solutions for many countries but has many weaknesses due to the difficulty of differentiating ASF from Classical Swine Fever and from other common endemic infectious diseases of swine that may present similar clinical signs.
3) Active surveillance programs are expensive and currently must rely on direct diagnostic tests such as viral isolation and nucleic acid-based assays because of challenges and weaknesses of antibody-based assays.
4) For persistent infections, effective surveillance would be difficult and costly since no signs exist to raise the flag of suspicion. Surveillance activities could be based on herd level stillborn rates or other reproductive parameters. However, such an indicator may lack the specificity to be economically feasible. This category of infection represents a critical vulnerability in the design of a comprehensive ASF surveillance system.

**Research needs**

1) Evaluate under experimental conditions the performance and overall accuracy of currently available ELISAs and PCR tests for surveillance.
2) Develop and evaluate novel tests such as ELISAs for both antigen and antibody detection for surveillance.
3) Develop tests for detecting ASFV in ticks.
4) To validate outbreak surveillance measures, epidemiological investigations need to be performed on the implementation of emergency control measures and the use of diagnostic tests to detect infected pigs in exposed populations.

**Feral Swine and Wild Suidae**

Feral swine and wild suidae may have an important role in the spread and maintenance of ASF. Research is needed to further our understanding of the potential role of feral swine as a reservoir for ASF.

**Tick Vector**

There is an important need to identify if the ticks in an affected region (where ASF outbreak occurred) could become biological vectors or not. Critical research includes studies to determine whether the new ASFV isolate can productively infect local ticks and whether they become persistently infected. Research is needed to further understand the distribution of soft ticks.
COUNTERMEASURES ASSESSMENT

ASSUMPTIONS

The following captures assumptions made by GARA working groups to assess potential countermeasures to enhance our ability to contain and eradicate an outbreak of ASF.

Situation
Countermeasures assessed for worst case scenario: A coordinated intentional distribution of ASFV-contaminated material in a high density highly populated pig region of an ASF-free country.

Target Population
Countermeasures assessed for target pig production segments in priority order:
1. Backyard pigs
2. Comprehensive commercial swine operations (farrowing, nursery, and finishing)
3. Commercial indoor farrowing operations
4. Large intensive indoor pig farms
5. Valuable commercial genetic swine stock

Scope of Outbreak
Countermeasures assessed for multiple outbreaks occurring simultaneously in backyard pigs, three farrowing commercial operations, a finishing pig commercial operation, a sow replacement operation, and evidence of infection in feral swine.

Vaccine Administration
No vaccine available, therefore the only control strategy would be based in the early detection of infected animals and their elimination, and strict control of the movement of pigs.
DECISION MODEL

The gap analysis working groups used the quantitative Kemper-Trego (KT) decision model to assess available vaccines and diagnostics, including experimental products. Instructions for using the model were provided prior to GARA scientific workshops (see Appendix I). Criteria and weights in the model were modified by the working groups for the purpose of assessing available countermeasures as well as experimental ASF vaccines and diagnostics (See Appendices II, III, IV, and V).

Criteria
The working groups selected critical criteria to enable the comparison of countermeasures using a pertinent and valid analysis, as follows:

Vaccines
- Efficacy
- Safety
- One dose
- Speed to scale-up
- Storage
- Distribution/Supply
- Mass administration
- DIVA compatible
- Withdrawal period
- Cost to implement (cost of goods, cost of replacement, inventory costs, cost to administer)

Diagnostics
- Sensitivity
- Specificity
- Direct (antigen/DNA) detection, DIVA during outbreak
- Indirect (antibody) detection DIVA general and post-outbreak surveillance
- Validation to purpose
- Speed of scale-up
- Throughput
- Pen-side test
- Rapid result
- Need for a confirmatory test
- Easy to perform
- Storage/Distribution/Supply
- Cost to implement

Weight
Each criterion was weighted to allow a quantitative comparison of the impact of the selected interventions.
**Product profile**
To ensure a consistent and meaningful assessment, the desired product profile (i.e., the benchmark) was identified for each countermeasure:

**Desired Vaccine Profile**
1. Highly efficacious: prevents transmission; efficacy in all age pigs, including maternal antibody override; one-year duration of immunity
2. Safe in all age pigs; no reversion to virulence for live vaccines
3. Only one dose is required
4. Rapid speed of production and scale-up, can deliver finished product quickly, and manufacturing method yields high number of doses
5. Expiration date of 24 months or greater
6. Manufacturer has effective storage and distribution capability
7. Quick onset of protection, 7-days or less
8. DIVA compatible: Can effectively and reliably differentiate infected from vaccinated animals
9. Short withdrawal period for food consumption
10. Cost of goods, cost of administration, cost of storage

**Desired Diagnostic Test Profile**
1. Detect all ASF genotypes
2. Direct tests for control and eradication
3. Indirect tests for post-control monitoring/detection subclinical cases
4. Rapid test- early detection
5. >95% specificity
6. >95% sensitivity
7. Pen-side test
8. DIVA Compatible
9. Field validated
10. Easy to perform/easily train personnel
11. Scalable
12. Reasonable cost

**Values**
The values assigned for each of the interventions reflect the collective best judgment of ASF working group members (see Appendices II, III, and IV).
VACCINES
The GARA gap analysis working groups noted that current research into a suitable vaccine for ASFV is limited to only a few research groups worldwide. A summary of experimental ASF vaccines reported in peer-reviewed scientific publications 2012-2018 is provided in Table II. To date, the most promising candidate vaccines are rationally attenuated gene-deleted recombinant live viruses. Previous work has highlighted both virulence and immunomodulation genes, which if removed would provide a strong candidate vaccine strain. The use of live attenuated viruses as vaccines is a well-established system with good protective attributes but evidence of reversion-to-virulence in some of the experimental vaccines tested to date is a concern. The use of recombination technology also allows for the insertion of suitable markers for the development of DIVA vaccines that would be particularly critical in any outbreak situation. There is currently no candidate isolate appropriately attenuated to ensure both safety and efficacy, but in the last few years several laboratories have progressed and are potentially getting closer to developing safe and effective experimental vaccine candidates. The alternative to a live attenuated virus that would remove any risk of reversion to virulence is the use of a subunit vaccine. This would satisfy both safety issues and ensure good DIVA characteristics. Although previous data indicated that such a strategy did not provide efficient protection against ASFV infection, there is currently some promising ongoing research into the feasibility of using such a strategy for producing an ASF vaccine. Collectively, progress in the development of a working vaccine and the preliminary results obtained to date indicate that a first generation vaccine may be feasible in the near future.

Summary
Vaccination against ASF is still not an option, but progress has been made towards the production of a rationally attenuated live virus vaccine.

Assessment of Experimental Vaccines
The GARA gap analysis working groups discussed the characteristics of the different available experimental vaccines. Following is a summary of the group’s opinion for each of them.

1) ASFV recombinant live attenuated gene-deleted vaccine: Attenuated by deletion of specific genes that have been identified as virulence determinants. As result, attenuated virus strains are produced which has been shown to effectively prevent disease in animals challenged with the parental virulent virus around 28 days post vaccination. The WG recognizes the effectiveness of this experimental vaccine in terms of inducing efficient protection with only one dose, the rapid onset/duration of the induced immunity and the safety of the product along with the molecular basis for the development of DIVA test. Lack of heterologous protection is recognized as its main deficiency, although recent results obtained with some of these vaccines showed the presence of cross protection among genotypically different isolates.

2) Subunit recombinant ASFV proteins expressed in different vaccine vectors: Different recombinant vectors containing individual ASFV gene/s have been used; e.g., vaccinia, raccoon pox, Ankara, swine pox, and human adenovirus. Safety, rapid onset of immunity, possibility of developing a DIVA test and the cost of implementation are recognized as the strength of these vaccine platforms. It is important to remark that so far, with the exception
of a very recent report showing preliminary data, there is no experimental evidence that an individual or a group of AFSV genes vectorized in any way can significantly protect domestic swine against the challenge with the homologous virus. Therefore, development of an ASFV subunit vaccine will depend on further research to identify protective antigens and the virus structures able to induce protection against the infection.

3) **ASFV DNA vaccines**: This is technically also a subunit vaccine where ASFV gene/s is cloned into DNA constructs that are used as immunogens. Its safety and the possibility to develop DIVA compatible diagnostic tests are the only strengths remarked by experts during the GARA Gap Analysis Workshops. As with vaccine candidates analyzed in (2) above, no candidate ASFV genes have to date been successfully identified so far to be used in a subunit vaccine.

Based in this assessment the ASFCWG decided that the most promising experimental vaccines are based on the use of rationally attenuated strains of ASFV. Nevertheless, the ASFCWG recognize that this candidate vaccine platform needs a great deal of experimental assessment in several aspects of its basic development, including induction of early immunity, development of a compatible DIVA test, and no reversion to virulence.

**DIAGNOSTICS**
The GARA gap analysis working groups determined the effectiveness of this countermeasure is high. Early detection of ASF is important to minimize spread of disease and reduce the economic impact. ASF surveillance in the U.S. is accomplished through a combination of passive and active surveillance programs. Diagnostic designed during the recovery phase post-outbreak are also essential.

**Summary**
- In case of any suspicious of the disease, virus and antibody detection techniques should be performed simultaneously.
- Antibody response to ASFV takes from 7-10 days. Animal surviving
- ASF virus can be detected from 2-3 dpi. The disease antibodies persist for long periods of time.
- Incubation periods, is around 3-15 days. The incubation period is usually 3–15 days. The more virulent strains produce peracute or acute haemorrhagic disease characterized by high fever, loss of appetite, haemorrhages in the skin and internal organs, and death in 3–10 days, sometimes even before the first clinical signs are observed.
Assessment of Laboratory and Commercial Diagnostic Tests (see Appendices III and IV). The ASFCWG identified and assessed six diagnostic tests to be used for surveillance, confirmation, and recovery. These tests are available for use in laboratories worldwide and one test is commercially available. The value of these tests was assessed against the desired diagnostic test profile for ASF control and eradication (See Decision Model, Appendix I).

1) **Virus isolation (VI)**
   Virus isolation in swine macrophages primary cell cultures is a classic technique for the detection of infectious virus. Virus infection is detected by hemadsorption or presence of cytopathogenic assay. The ASFCWG stressed the attributes of VI, including the specificity and sensitivity of the technique as well as the fact that results do not need further confirmation. However, the technique presents disadvantages as it takes several days to run the test, is difficult to scale up, the impossibility to adapt the technique in a throughput system, and the need for technical expertise to perform the test.

2) **Conventional RT-PCR.** This technique is based in the use of specific primers for conserved areas of p72. The technique present good specificity and sensitivity, has been validated, is easily scaled up and results are quickly obtained. Unfortunately, results need to be corroborated by a confirmatory technique and it is necessary to have technical expertise to perform the test.

3) **Real time RT-PCR.** The test present good specificity, results are quickly available, is easy to be adapted in a throughput system and easily scaled up. As with the conventional PCR, results need to be corroborated by a confirmatory technique and it is necessary to have technical expertise to perform the technique.

4) **Fluorescent antibody tests (FAT).** The assay consists of detecting virus in tissues of infected animals using fluorescent anti-ASFV specific antibodies. This test has high specificity, results quickly available, has been validated, is inexpensive, and provides definitive results. The disadvantages of this test are the difficulties for scaling up or set up in a throughput system, and it needs to be performed by a highly trained operator.

5) **Antigen ELISA.** This assay allows the detection of virus using a capture ELISA based on the use of anti-ASFV antibodies on the plate. The specificity is good, although the sensitivity is poor. This technique is easily scaled up as well as adapted to a throughput system. Additionally, it is easy to perform and results are obtained quickly. Beside its poor sensitivity, another disadvantage of the technique is lack of validation, it is expensive and results need to be confirmed by a second technique.

6) **Multiplex PCR assays:** A multiplex conventional RT-PCR is available for simultaneous and differential detection of ASFV and Classical Swine Fever Virus (CSFV) (Agüero et al., 2004). The method is highly sensitive and specific and has been validated using field and experimental porcine clinical material. This test can be useful in case of clinical suspicion of swine hemorrhagic disease, as well as in those countries/areas where both viruses can be co-circulating at any time.
Assessment of Experimental Diagnostic Tests

The GARA gap analysis working groups identified and discussed several new technologies that are being considered for the detection of ASF in the laboratory or as pen-side tests for field use.

1) Loop mediated isothermal amplification (LAMP): LAMP is based on amplification of nucleic acids without the need of PCR equipment. It requires only the combined use of a DNA polymerase with strand-displacement activity and four-six specially designed primers towards six regions of the DNA target (Notomi et al., 2000). LAMP is described as a highly specific and sensitive tool, which allows the detection of amplified products even by the naked eye. The comparative simplicity of the technology makes LAMP adaptable to frontline testing in regional laboratories, simple diagnostic situations and even to pen-side testing as a rapid first-line tool. Several LAMP assays have been developed recently for ASFV detection, and standardisation and validation are currently ongoing (Hertjner and Allan, QUB, Belfast, UK).

2) Real-time PCR assays using commercial universal probe libraries (UPL): UPL was recently commercialized by Roche Applied Science, and is a collection of short hydrolysis DNA probes, originally designed for gene expression analysis and offered as a universal detection system. Currently, UPL probes are being applied also for pathogen detection, main advantages being reasonably low cost, short time of delivery, and ready-to-use format. The combination of a specific primer set and an appropriate UPL probe will allow specific and sensitive detection of ASFV by real-time PCR at a comparably lower cost. Two UPL real-time PCR assays, designed in different viral genome regions, have been developed and standardised recently for ASFV detection (Fernández-Pinero, Gallardo, and Arias, CISA-INIA, Valdeolmos, Spain). Validation for their suitability in diagnosis is in progress.

3) Linear-After-The-Exponential (LATE)-PCR: LATE-PCR is an advanced asymmetric PCR producing huge amount of ssDNA molecules, which are detected by the incorporation of a specific low-Tm probe. This tool provides several advantages, such as increased multiplexing capacity and faster thermocycling, compared to currently used PCR chemistries (Sánchez et al., 2004). A LATE-PCR method has just been developed for ASFV detection (Hakhverdyan, Stahl, and Belák, SVA, Uppsala, Sweden; in cooperation with Ronish and Wangh, Brandeis University, USA). The LATE technology is exclusively licensed by Smiths Detection, and the developed ASF assay will be adapted to their portable PCR platform BioSeeq to provide a robust, powerful and simple-to-use diagnostic system for onsite detection of ASFV in a wide range of environmental conditions.

4) Lateral flow device (LFD): A one-step immunochromatographic strip (pen-side test) capable of specifically detecting anti-ASF antibodies in serum specimens is under development. The qualitative assay is based on a direct immunoassay in which the detector reagent is latex micro particles covalently coated with a purified ASFV protein. The capture reagent is a viral protein adsorbed on the nitrocellulose membrane strip to form a test line. A second line created above the test line, by the immobilization of anti-control protein antibodies, is used as a control of the test. A serum specimen is applied to the sample pad. The anti-specific antibodies present in the sample specifically bind to the labelled micro particles. The antibody-protein binding complex formed migrates until the nitrocellulose membrane by the
flow caused by capillary action and reacts with the immobilized viral protein, which generate a visible test line.

**DISINFECTANTS/INACTIVATION**
The survivability of ASFV in feces and urine of experimentally infected animals was recently investigated by Davies *et al.*, 2017. Based on the calculated half-lives it can be assumed that ASPV remains infectious at 37°C for almost four (urine) or three (feces) days. In a study by Turner and William in 1999, it was shown that at 40°C, the inactivation of ASFV in pig manure is realized after 4 hours, and within 5 minutes at 65°C (See Table 4).

**Disinfectants**
The use of effective disinfectants for cleaning infected premises, trucks, and fomites is an important measure for preventing new introductions of ASF. However, many of the common disinfectants are ineffective. Care should be taken to use a disinfectant specifically approved for ASFV. A number of inactivation methods and disinfectants have been tested and reported for various materials, including animal waste. See Table IV for a complete list of disinfectants, field application, effective concentrations, exposure time, and references.

**Rendering**
Rendering of animal byproducts is heavily regulated in Europe and involves sterilization at 3 bar and 133°C for at least 20 min. Any process that exceeds 70°C for 20 min (or 60°C for 30 min) will inactivate ASFV; therefore, the rendering process will inactivate ASFV.

**Biogas plant**
African swine fever viruses can also be inactivated in a correctly operated biogas plant within hours (thermophilic) or days (mesophilic). The process does not only have temperature effects that inactivate the virus (pH value, metabolites, etc.). Nevertheless, it must be kept in mind that biogas plants are generally not designed in such a way that a strict black/white separation can take place (in contrast to high-security laboratories or modern rendering plants). For this reason, additional measures (preheating, adaptation of the process organization) would be necessary to achieve safe inactivation and protection against recontamination. In the doctoral thesis of Andres Moss (Moss A. 2001), a preheating of materials of animal origin to at least 70°C was proposed. However, this would be difficult to implement under field conditions.

**Carcass Burial**
Studies to assess ASFV inactivation in buried carcasses and soil are on-going but not yet completed at the time of publishing this report. For soil, the pH found in forest seems to be a limiting factor for virus survival. This report will be updated when the results of these experiments are completed.

**ACARICIDES**
Acaricides for controlling the soft tick may not be useful as the tick lives off the host and burrows underground as well as crevices in buildings. The best ASF method is to remove the pigs from infected premises.
**Drugs**
There are no licensed anti-viral drugs available to treat pigs against ASF. Several publications reported compounds with potent anti-ASFV activity (Quetglas *et al*., 2012; Hakobyan *et al*., 2017; Barrado-Gil *et al*., 2017, etc.). Some of them are FDA-approved drugs but also active natural products (Fabregas *et al*., 1999; Galindo *et al*., 2011). However, the analysis of their potential use or applications in ASF remain unexplored. Antiviral drugs could be useful to complement vaccination or stamping out strategies from an epidemiological and economic point of view. One example was demonstrated for classical swine fever (CSF), another epizootic disease of pigs where outbreaks in areas of high pig density were controlled effectively with antiviral drugs combined with other common countermeasures such as massive culling and emergency vaccination (Backer *et al*., 2013). Possible benefits in ASFV would be the potential reduction of virus titers in blood and virus excretion from infected animals, and the reduction of the risk of dissemination until culling is possible. Thus, antivirals could potentially reduce transmission and prevent dissemination in susceptible animals around affected farms (belt-containment strategy). These compounds might be used as supplements in combined antiviral plus vaccination strategies to reduce virus persistence of live attenuated vaccines; however, an assessment of their potential use remains a gap. One antiviral tested, lipophilic statins, showed some activity against ASFV (Quetglas *et al*., 2012), demonstrating its potential use as a vaccine adjuvant (Xia *et al*., 2018). Further studies are needed to understand the mechanisms of action of antivirals, which may in turn inform the development of new vaccine candidates.

**Personal Protective Equipment (PPE)**
ASF is not a human pathogen. PPE should be suitable to prevent farm-to-farm virus spread by animal health officials involved in eradication.
RECOMMENDATIONS

RESEARCH
The GARA recommends the implementation of the following research priorities to advance our ability to rapidly detect, control and respond to an ASF outbreak, including the progressive control and eradication of ASF in endemic settings.

Virology
- African swine fever virus complete genomic sequences from each genotype, viruses with different virulence, and viruses that have replicated exclusively in domestic pigs, wild pigs and ticks
- Generation of reference sequences that have been confirmed by different techniques in different laboratories to account of sequencing errors in repeat regions and other difficult stretches.
- Harmonization of sequencing workflows and validation of different enrichment techniques and host exclusion.
- ASFV bioinformatics resource to establish a comprehensive database that will include full length genome sequence of large number of isolates to replace the current less meaningful genotype based classification.

Viral Pathogenesis
- Basic parameters governing host to host infection, including domestic and wild swine as well as the arthropod host.
- Study the pathogenesis of ASFV isolates with different virulence in diverse susceptible host.
- Determine patterns of activation of immunologically relevant host genes particularly at early stages after infection.
- Identify ASFV genes and genetic determinants (group of genes like multigene families) involved in host range, virulence and pathogenicity. Correlate transcriptomics and proteomics.
- Continued investigation of determinants of virulence for different genotype and ASFV strains.

Immunology
- Discovery of the immune mechanism mediating effective homologous and heterologous protection against virus infection.
- Identification of viral genetic patterns that correlate with presence/absence of homologous versus heterologous protection.
- Identification of virus protein's involved in the induction of protective immune response.
- Identify regulatory genes involved in pro-inflammatory cytokines and antibodies production and the assessment of their actual role in the process of virus infection/virulence in swine.
- Explore the development of new assays based on cellular immunity for the early detection of the disease.
• Explore immune-pathogenesis including T-cell responses and MHC presentation.
• Improve our understanding of the role of multigene families in antigenic variability and evasion of immune response.
• Identify and characterize genes related to host protection.

**Epidemiology**

• A global ASF surveillance system that provides high quality, accurate, and real-time information on ASF risk is needed to cover critical gaps of information of the ASF situation worldwide and to support ASF control and eradication on a global scale.
• Continuing molecular epidemiology studies to monitor both captive and wild suid populations as well as soft tick distribution is essential to effectively address the ASFV problem in endemic areas. These studies are also of great importance for preventive and surveillance programs.
• Conduct field validation of existing ELISA for the detection of tick presence.
• Need to intensify virus detection, isolation and characterization from sylvatic cycle hosts in Africa for genotyping purposes.
• Ongoing biological and molecular characterization of currently circulating isolates in Africa and Europe.
• To identify and apply new phylogenetic markers associated with virus virulence to understand virus evolution in endemic areas.
• To better understand the socioeconomics of the disease and pig and pork value chains, particularly those related to low biosecurity settings.
• To better understand the costs (direct and indirect) of ASF, both in epidemic and endemic situations.
• Identify management tools to control the disease in wild boar
• To better understand the role played by the environmental contamination and blood sucking insects in the disease cycle.
• Improved knowledge of the role of the survivor pigs as potential shedders by the use of appropriated diagnostic serological and virological tests for identification/detection of these animals.

**Surveillance**

• Further evaluate performance and overall accuracy of currently available ELISAs and PCR tests under experimental and field conditions. Evaluate under experimental conditions the performance and overall accuracy of currently available ELISAs and PCR tests.
• Automation and standardization of viral genome sequencing for subtyping ASFV strains
• Assess the rate of transmission of strains of ASFV of different virulence in infected-contact animal experiments.
• The epidemiology of ASF in emergency control programs needs to be assessed and modelled on the level of the individual pig, the herd, and the demographics of the region (low versus high density pig populations).
• Risk assessments need to be performed with regard to control or spread of ASFV
**Diagnostics**

- Support the development of new technologies for pen-side testing
- Evaluate and validate commercially available pen-side tests to “fit for purpose” for surveillance, response, and recovery
- Identify/develop cell lines that replace primary cultures for improved virus isolation techniques.
- Full validation of novel or modified ELISA tests for detection of antibodies in alternative sample types (e.g., blood, exudate’s tissues, oral fluids, meat juice, filter papers, etc.).
- Improved stability of reagents in commercial diagnostic kits (molecular virological and serological assays) regarding shipment and expiration issues. This could be overcome by exploring different strategies such as gelification lyophilization and others.
- Expanded field validation of novel assays, taking into consideration the worldwide scenarios.
- Development and evaluation of non-invasive sampling methodologies in wild suids.
- Validate available penside diagnostic tools to enhance detection and improve surveillance in wild life in Africa.
- Development, evaluation and field validation of commercial confirmatory serological tests.
- Standardization and validation of ELISA tests to detect antibodies against *Ornithodoros* tick saliva antigens in bitten animals.
- Study the effects and detection of low virulent isolates and persistent infections

**Vaccines**

- ASFV virology and functional genomics studies to inform vaccine discovery research.
- Determine safety characteristics associated with experimental live attenuated vaccines.
- Identify alveolar macrophage genes that enable ASF viral growth to inform the development of a cell line for vaccine production.
- Further explore the engineering of gene-deleted ASFV as potential vaccine candidates.
- There is a need for inter-laboratory testing of vaccine candidates.
- Harmonize challenge tests and read-outs.
- Continue to explore the potential for effective subunit vaccines.
- Research potential antigenic vaccine markers to differentiate infected from vaccinated animals (DIVA).
- Develop baits to enable the effective oral vaccination of wild boars.
- Develop and validate effective parenteral routes for live vaccine administration
- Proof-of-concept testing of needle-free systems for the delivery of new ASF molecular vaccines.

**Biotherapeutics**

- Testing Ad5-IFN distribution and expression in swine for rapid onset of protection against ASFV infection.
Disinfectants
- Development of low cost commercially available disinfectants for use in the inactivation of ASFV on contaminated surfaces found in farm settings and other susceptible environments.
- Explore the use of disinfectants to reduce the risk of ASFV infections from ASFV-infected carcasses.

Feral Swine and Wild Suidae
- Conduct research projects to further our understanding of the potential role of feral swine and wild suids as a reservoir for ASF.

Tick Vector
- Identify if the ticks in new geographical areas where ASF outbreak occur could become biological vectors or not.
- Determine whether new ASFV isolates can productively infect local ticks and whether they become persistently infected.
- Research is needed to further understand the distribution of soft ticks.

PREPAREDNESS
Many of the countermeasures discussed in this report will require planning, preparation, and integration into a coordinated disease control program. Critical will be funding for veterinary medical countermeasures to be stockpiled for use in an emergency response plan for an outbreak of ASF. The GARA recommends investing in the implementation of research priorities to support preparedness plans and ensure the effective use of countermeasures to prevent, control, and eradicate ASF.
CONCLUSION

African swine fever is a transboundary animal disease that currently threatens swine production worldwide. Even though ASF is an African disease, it is now well entrenched in the Caucasus, Russia, Europe, and currently threatening Asia. The most significant cause of this recent geographical spread is most likely due to the illegal movement of animals, trade, and contaminated products. This places other countries that trade in pig and pig products in danger, including Europe, South America, and North America. Furthermore, the epidemiological implications of ASF outbreaks in new geographical and ecologically unique environments are unknown, complicating control measures. Surveillance programs will be the first line of defense against ASF. Diagnostic tests are available and need to be incorporated in diagnostic laboratories. A key control measure will be vaccines but they are currently unavailable, a major gap in the availability of countermeasures to control ASF outbreaks.
FIGURE 1: ASFV PHYLOGENETIC ANALYSIS

Figure 1: The extent of the ASF virus diversity as revealed by a phylogenetic tree of p72 genotyping revealing ASF Genotypes (Quembo CJ et al, 2018)
# TABLE I: ASF OUTBREAKS 2007-2018

<table>
<thead>
<tr>
<th>COUNTRY</th>
<th>DATE OF LAST ASF OUTBREAK</th>
<th>REFERENCE/SOURCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>China</td>
<td>August 2018</td>
<td><a href="http://www.thepigsite.com">www.thepigsite.com</a></td>
</tr>
<tr>
<td>Romania</td>
<td>August 2018</td>
<td><a href="https://www.brownsvilleherald.com">https://www.brownsvilleherald.com</a></td>
</tr>
<tr>
<td>Malawi</td>
<td>July 2018</td>
<td>outbreaknewstoday.com/Malawi</td>
</tr>
<tr>
<td>Hungary</td>
<td>April 2018</td>
<td><a href="https://www.pigprogress.net/Health">https://www.pigprogress.net/Health</a></td>
</tr>
<tr>
<td>South Africa</td>
<td>May 2018</td>
<td><a href="https://www.reuters.com">https://www.reuters.com</a></td>
</tr>
<tr>
<td>Tanzania</td>
<td>May 2018</td>
<td><a href="http://www.xinhuanet.com">www.xinhuanet.com</a></td>
</tr>
<tr>
<td>Poland</td>
<td>Jan. 2018</td>
<td><a href="https://www.pigprogress.net">https://www.pigprogress.net</a></td>
</tr>
<tr>
<td>Uganda</td>
<td>2018</td>
<td>Charles Masembe personal communication</td>
</tr>
<tr>
<td>Zambia</td>
<td>2018</td>
<td><a href="https://www.farmersweekly.co.za">https://www.farmersweekly.co.za</a></td>
</tr>
<tr>
<td>Ghana</td>
<td>2018</td>
<td><a href="http://www.thepigsite.com">www.thepigsite.com</a></td>
</tr>
<tr>
<td>Côte d’Ivoire</td>
<td>Sept 2017</td>
<td><a href="https://www.oie.int">https://www.oie.int</a></td>
</tr>
<tr>
<td>Czech Republic</td>
<td>June 2017</td>
<td><a href="http://www.izs.it">www.izs.it</a></td>
</tr>
<tr>
<td>Russia</td>
<td>2018 (Since 2007)</td>
<td><a href="http://www.thepigsite.com">www.thepigsite.com</a></td>
</tr>
<tr>
<td>Country</td>
<td>Year(s)</td>
<td>Additional Information</td>
</tr>
<tr>
<td>------------------</td>
<td>---------</td>
<td>----------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Cape Verde</td>
<td>2015</td>
<td><a href="http://www.thepigsite.com">www.thepigsite.com</a></td>
</tr>
<tr>
<td>Zimbabwe</td>
<td>2015</td>
<td><a href="https://www.wattagnet.com">https://www.wattagnet.com</a></td>
</tr>
<tr>
<td>Chad</td>
<td>2014</td>
<td><a href="https://www.wattagnet.com/.../20071-chad-has-first-african-swine-fever-outbreak-sinc">https://www.wattagnet.com/.../20071-chad-has-first-african-swine-fever-outbreak-sinc</a>...</td>
</tr>
<tr>
<td>Angola</td>
<td>2011</td>
<td><a href="http://www.healthmap.org/site/diseasedaily/article/african-swine-fever-angola-12611">www.healthmap.org/site/diseasedaily/article/african-swine-fever-angola-12611</a></td>
</tr>
<tr>
<td>Cameroon</td>
<td>2011</td>
<td><a href="https://www.pigprogress.net/.../African-Swine-Fever-hits-Cameroon-100000-animals-co...">https://www.pigprogress.net/.../African-Swine-Fever-hits-Cameroon-100000-animals-co...</a></td>
</tr>
<tr>
<td>Madagascar</td>
<td>2010</td>
<td>Charles Masembe personal communication</td>
</tr>
<tr>
<td>Democratic</td>
<td>2010</td>
<td>Charles Masembe personal communication</td>
</tr>
<tr>
<td>Congo</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Namibia</td>
<td>2009</td>
<td><a href="https://www.pigprogress.net/">https://www.pigprogress.net/</a></td>
</tr>
<tr>
<td>Georgia</td>
<td>2007</td>
<td><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634662/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634662/</a></td>
</tr>
<tr>
<td>Senegal</td>
<td>2007</td>
<td><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204638/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204638/</a></td>
</tr>
</tbody>
</table>

## TABLE II: SUMMARY OF COMPLETE GENOMES AVAILABLE ON NCBI

<table>
<thead>
<tr>
<th>Name</th>
<th>Assession</th>
<th>Collection date</th>
<th>Country</th>
<th>Host</th>
</tr>
</thead>
<tbody>
<tr>
<td>Odintsovo_02/14</td>
<td>KP843857.1</td>
<td>2014</td>
<td>Russia</td>
<td>Wild Boar</td>
</tr>
<tr>
<td>26544/OG10</td>
<td>KM102979.1</td>
<td>2010</td>
<td>Italy: Sardinia</td>
<td>Domestic pig</td>
</tr>
<tr>
<td>47/Ss/2008</td>
<td>KX354450.1</td>
<td>2008</td>
<td>Italy: Province of Sassari, Sardinia</td>
<td>Domestic pig</td>
</tr>
<tr>
<td>Georgia 2007/1</td>
<td>FR682468.1</td>
<td>2007</td>
<td>Georgia</td>
<td>Domestic pig</td>
</tr>
<tr>
<td>Ken06.Bus</td>
<td>KM111295.1</td>
<td>2006</td>
<td>Kenya</td>
<td>Domestic pig</td>
</tr>
<tr>
<td>Ken05/Tk1</td>
<td>KM111294.1</td>
<td>2005</td>
<td>Kenya</td>
<td>Tick</td>
</tr>
<tr>
<td>OURT 88/3</td>
<td>AM712240.1</td>
<td>1988</td>
<td>Portugal: Alentejo</td>
<td>Tick</td>
</tr>
<tr>
<td>Pretorisuskop/96/4</td>
<td>AY261363</td>
<td>1996</td>
<td>South Africa: Kruger National Park</td>
<td>Tick</td>
</tr>
<tr>
<td>Malawi Lil-20/1</td>
<td>AY261361</td>
<td>1983</td>
<td>Malawi: Calaswa</td>
<td>Tick</td>
</tr>
<tr>
<td>Mkuzi 1979</td>
<td>AY261362.1</td>
<td>1979</td>
<td>South Africa: Mkuzi Game Reserve</td>
<td>Tick</td>
</tr>
<tr>
<td>BA71V</td>
<td>NC_001659.2</td>
<td>1971</td>
<td>Spain</td>
<td>Vero adapted</td>
</tr>
<tr>
<td>NHV</td>
<td>KM262846</td>
<td>1968</td>
<td>Portugal</td>
<td>Domestic pig</td>
</tr>
<tr>
<td>Tengani 62</td>
<td>AY261364</td>
<td>1962</td>
<td>Malawi: Tengani, Nsanje District</td>
<td>Domestic pig</td>
</tr>
<tr>
<td>L60</td>
<td>KM262844</td>
<td>1960</td>
<td>Portugal</td>
<td>Domestic pig</td>
</tr>
<tr>
<td>Kenya 1950</td>
<td>AY261360</td>
<td>1950</td>
<td>Kenya</td>
<td>Domestic pig</td>
</tr>
<tr>
<td>E75</td>
<td>FN557520.1</td>
<td>1975</td>
<td>Spain</td>
<td>Domestic pig</td>
</tr>
<tr>
<td>warthog</td>
<td>AY261366.1</td>
<td>Pre-2003</td>
<td>Namibia</td>
<td>Warthog</td>
</tr>
<tr>
<td>Warmbaths</td>
<td>AY261365</td>
<td>Pre-2003</td>
<td>South Africa: Warmbaths</td>
<td>Tick</td>
</tr>
<tr>
<td>Benin 97/1</td>
<td>AM712239.1</td>
<td>1997</td>
<td>Benin</td>
<td>Domestic pig</td>
</tr>
<tr>
<td>Type of Vaccine</td>
<td>Reference</td>
<td>Protection</td>
<td>Safety</td>
<td></td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------------------------------------------------------------------------------------</td>
<td>------------</td>
<td>---------</td>
<td></td>
</tr>
<tr>
<td>Subunit vaccine: Immunization of pigs by DNA and recombinant vaccinia virus identify ASFV immunogenic proteins.</td>
<td>J Virol. 2018  pii: JVI.02219-17 9</td>
<td>No</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>LAV: Protection of pigs with deletion mutant of MGF genes in ASFV Benin by different doses and routes.</td>
<td>Vaccine. 2018 36:707-715</td>
<td>Yes</td>
<td>Not Tested</td>
<td></td>
</tr>
<tr>
<td>LAV: Adapted ASFV strain Congo is a LAV protecting against parental virulent virus.</td>
<td>Arch Virol. 2017 10(3081-3088)</td>
<td>Yes</td>
<td>Not Tested</td>
<td></td>
</tr>
<tr>
<td>LAV: Naturally attenuated ASFV OURT88/3 protects against virulent homologous field isolate.</td>
<td>Antiviral Res. 2017 138:1-8</td>
<td>Yes</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>LAV: Deletion of 9GL in Pret4 strain protects against challenge with virulent parental isolate</td>
<td>Viruses. 2016 8(10). pii: E291</td>
<td>Yes</td>
<td>Not Tested</td>
<td></td>
</tr>
<tr>
<td>LAV: Deletion of MGF genes in ASFV Benin isolate reduces virulence in domestic pigs and induces a protective response.</td>
<td>Vaccine. 2016 34(39):4698-4705</td>
<td>Yes</td>
<td>Not Tested</td>
<td></td>
</tr>
<tr>
<td>LAV: ASFV Georgia isolate harboring deletions of 9GL and MGF360/505 genes is highly attenuated but does not confer protection against parental virus challenge.</td>
<td>Virus Res. 2016 Aug 2;221:8-14</td>
<td>No</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>LAV: Naturally attenuated ASFV OURT88/3 Induces Protection Against Challenge with Virulent Strains of Genotype I.</td>
<td>Transbound Emerg Dis. 2016 63(5):e323-7</td>
<td>Yes</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Subunit vaccine: Inactivated virus and use of Modern adjuvants do not enhance the efficacy of an ASFV vaccine.</td>
<td>Vaccine. 2014 Jun 30;32(31):3879-82</td>
<td>No</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>LAV: 9GL and UK genes deletion from attenuated ASFV OUR T88/3 decreases its ability to protect against challenge.</td>
<td>Virology. 2013 Aug 15;443(1):99-105</td>
<td>No</td>
<td>No Tested</td>
<td></td>
</tr>
<tr>
<td>Subunit vaccine: DNA immunization partially protects pigs against sublethal challenge ASFV.</td>
<td>Antiviral Res. 2013 98(1):61-5</td>
<td>No</td>
<td>Yes</td>
<td></td>
</tr>
</tbody>
</table>
### TABLE IV: DISINFECTANTS FOR INACTIVATING AFRICAN SWINE FEVER VIRUS

<table>
<thead>
<tr>
<th>Disinfectant</th>
<th>Field of application</th>
<th>Concentration</th>
<th>Exposure time</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sulfuric acid</td>
<td>surface disinfectant</td>
<td>1%</td>
<td>15 min</td>
<td>Fauser-Leiensetter, 2000</td>
</tr>
<tr>
<td></td>
<td>liquid manure</td>
<td>1%</td>
<td>recommendation: 1 week</td>
<td>Fauser-Leiensetter, 2000</td>
</tr>
<tr>
<td>Formic acid</td>
<td>surface disinfectant</td>
<td>1%</td>
<td>15 min</td>
<td>Fauser-Leiensetter, 2000</td>
</tr>
<tr>
<td></td>
<td>liquid manure</td>
<td>4%</td>
<td>recommendation: 1 week</td>
<td>Fauser-Leiensetter, 2000</td>
</tr>
<tr>
<td>Peracetic acid</td>
<td>surface disinfectant</td>
<td>2%</td>
<td>15 min</td>
<td>Fauser-Leiensetter, 2000</td>
</tr>
<tr>
<td>Formaldehyde</td>
<td>surface disinfectant</td>
<td>0%</td>
<td>15 min</td>
<td>Fauser-Leiensetter, 2000</td>
</tr>
<tr>
<td></td>
<td>liquid manure</td>
<td>1%</td>
<td>recommendation: 1 week</td>
<td>Fauser-Leiensetter, 2000</td>
</tr>
<tr>
<td></td>
<td>liquid manure</td>
<td>0.50%</td>
<td>&gt; 4 days</td>
<td>Shirai et al., 1999, zitiert im EFSA Scientific Review</td>
</tr>
<tr>
<td>Sodium dodecyl sulfate</td>
<td>surface disinfectant</td>
<td>3%</td>
<td>15 min</td>
<td>Fauser-Leiensetter, 2000</td>
</tr>
<tr>
<td></td>
<td>liquid manure</td>
<td>3%</td>
<td>recommendation: 1 week</td>
<td>Fauser-Leiensetter, 2000</td>
</tr>
<tr>
<td>Glutaraldehyde solution</td>
<td>surface disinfectant</td>
<td>1%</td>
<td>30 min</td>
<td>Fauser-Leiensetter, 2000</td>
</tr>
<tr>
<td></td>
<td>liquid manure</td>
<td>1%</td>
<td>recommendation: 1 week</td>
<td>Fauser-Leiensetter, 2000</td>
</tr>
<tr>
<td></td>
<td>tissue</td>
<td>0.2 %</td>
<td>11 days</td>
<td>Cunliffe et al., 1979, zitiert im EFSA Scientific Review</td>
</tr>
<tr>
<td>Sodium hydroxide solution</td>
<td>surface disinfectant</td>
<td>0.50%</td>
<td>30 min</td>
<td>Fauser-Leiensetter, 2000</td>
</tr>
<tr>
<td></td>
<td>liquid manure</td>
<td>4%</td>
<td>recommendation: 1 week</td>
<td>Fauser-Leiensetter, 2000</td>
</tr>
<tr>
<td></td>
<td>liquid manure</td>
<td>1%</td>
<td>150 s (4°C)</td>
<td>Turner und Williams, 1999</td>
</tr>
<tr>
<td></td>
<td>liquid manure</td>
<td>1%</td>
<td>30 min (4 °C)</td>
<td>Turner und Williams, 1999</td>
</tr>
<tr>
<td>Citric acid</td>
<td>surface disinfectant</td>
<td>2%</td>
<td>30 min (22°C)</td>
<td>Krug et al., 2012</td>
</tr>
<tr>
<td>Caustic lime</td>
<td>dung pack</td>
<td></td>
<td></td>
<td>Bergerdorf et al., 1989, cited by Haas et al., 1995</td>
</tr>
<tr>
<td>Iodine</td>
<td></td>
<td>0.015 bis 0.0075 % (potassium iodide)</td>
<td></td>
<td>Shirai et al., 1999</td>
</tr>
<tr>
<td>Ortho-phenylphenol</td>
<td></td>
<td>1%</td>
<td>1 h</td>
<td>EFSA Scientific Review; OIE; Stone und Hess, 1973</td>
</tr>
<tr>
<td>Chloride, Hypochlorite</td>
<td>surface disinfectant</td>
<td>0.03 bis 0.0075 % sodium hypochloride</td>
<td></td>
<td>Shirai et al., 1999, zitiert im EFSA Scientific Review</td>
</tr>
<tr>
<td></td>
<td>disinfection method</td>
<td>concentration</td>
<td>duration</td>
<td>source</td>
</tr>
<tr>
<td>----------------</td>
<td>-----------------------</td>
<td>------------------------</td>
<td>-------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>surface disinfectant</td>
<td>2,3 % Chlor</td>
<td>30 min</td>
<td></td>
<td>OIE</td>
</tr>
<tr>
<td>surface disinfectant</td>
<td>0,15 % / 0,2 %</td>
<td>Krug et al., 2012</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Quarterary ammonium compounds</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quarterary ammonium compounds</td>
<td>surface disinfectant</td>
<td>0.003%</td>
<td></td>
<td>Shirai et al., 1999, zitiert im EFSA Scientific Review</td>
</tr>
<tr>
<td>Lime Ca(OH)₂</td>
<td>liquid manure</td>
<td>1%</td>
<td>150 s (4°C)</td>
<td>Turner und Williams, 1999</td>
</tr>
<tr>
<td>liquid manure</td>
<td>1%</td>
<td></td>
<td>30 min (4 °C)</td>
<td>Turner und Williams, 1999</td>
</tr>
<tr>
<td>Heat</td>
<td>pig slurry</td>
<td>65 °C</td>
<td>5 min</td>
<td>Turner und Williams, 1999</td>
</tr>
</tbody>
</table>
APPENDIX I: COUNTERMEASURES WORKING GROUP INSTRUCTIONS

**Decision Model**

We will use a decision model to assess potential countermeasures to stockpile. These countermeasures must significantly improve our ability to control and eradicate an outbreak of African Swine Fever (ASF) in an ASF-free country such as the United States. The decision model is a simple tool that will allow us to focus on critical criteria for the National Veterinary Stockpile, and rank the available interventions relative to each other. The decision model is available as a Microsoft Excel spread sheet, which has been prepared to quantitatively assess the rankings we assign to a set of selected criteria that will lead to the selection of the highest cumulative option. We can use as many criteria as we want but the objective is to get down to the ones that will make or break success. The criteria for each intervention will be selected by the ASF Countermeasures Working Group, but a preliminary set has been identified to expedite the process. You are encouraged to review the criteria prior to coming to the meeting and be prepared to modify the criteria as needed with the working group. The following provides an example of criteria and assumptions for assessing vaccines.

**Criteria**

If a vaccine is going to be used as an emergency outbreak control tool for ASF, then we need to know: 1) is it efficacious (does it effectively eliminate shedding or just reduce shed by a known log scale); 2) does it work rapidly with one dose (probably do not have time for a second dose); 3) whether it is available today from the perspective of having a reliable & rapid manufacturing process (need to know it can be up & running rapidly and will yield a predictable amount of vaccine; 4) can we get the product to the outbreak site rapidly & safely; 5) once at the site, can we get it into the target population rapidly; 6) type of administration- mass or injected, people and equipment to do the job become important); and 7) are diagnostics available to monitor success and or DIVA compliant. While cost is important, the cost of the vaccine in an outbreak will be small in comparison to the other costs. In addition, how fast the product can be made is important because that will have a big impact on how big a stockpile will be needed. Accordingly, you will see from the Excel sheets that have been prepared for vaccines that the following critical criteria and assignment of weights for each criterion are proposed.

<table>
<thead>
<tr>
<th>Weight</th>
<th>Critical Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>Efficacy</td>
</tr>
<tr>
<td>6</td>
<td>Safety</td>
</tr>
<tr>
<td>8</td>
<td>One dose</td>
</tr>
<tr>
<td>6</td>
<td>Speed of Scale up</td>
</tr>
<tr>
<td>2</td>
<td>Shelf life</td>
</tr>
<tr>
<td>2</td>
<td>Distribution/storage</td>
</tr>
<tr>
<td>10</td>
<td>Quick Onset of Immunity</td>
</tr>
<tr>
<td>8</td>
<td>DIVA Compatible</td>
</tr>
<tr>
<td>2</td>
<td>Withdrawal</td>
</tr>
<tr>
<td>2</td>
<td>Cost to Implement</td>
</tr>
</tbody>
</table>

Cyril Gerard Gay, DVM, Ph.D
Senior National Program Leader
Animal Production and Protection
Agricultural Research Service
### APPENDIX II: EXPERIMENTAL VACCINES

#### Experimental Vaccines for ASF

**Rank each Intervention (2, 4, 6, 8, or 10) as to its importance to making a decision, only one “10” rankings allowed.**

<table>
<thead>
<tr>
<th>Weight</th>
<th>Critical Criteria</th>
<th>Recombinant Gene Deleted</th>
<th>Recombinant Vaccinia-vectored</th>
<th>Recombinant Swinepox-Vectored</th>
<th>DNA Vaccine</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>Efficacy</td>
<td>10</td>
<td>4</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>8</td>
<td>Safety</td>
<td>8</td>
<td>8</td>
<td>4</td>
<td>10</td>
</tr>
<tr>
<td>8</td>
<td>One dose</td>
<td>8</td>
<td>6</td>
<td>6</td>
<td>2</td>
</tr>
<tr>
<td>8</td>
<td>Cross-Protection</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>10</td>
<td>Onset of Immunity</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>2</td>
</tr>
<tr>
<td>4</td>
<td>Distribution/Supply</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>6</td>
<td>Mass Administration</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>4</td>
</tr>
<tr>
<td>6</td>
<td>Duration of Immunity</td>
<td>8</td>
<td>6</td>
<td>6</td>
<td>4</td>
</tr>
<tr>
<td>8</td>
<td>DIVA Compatible</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>6</td>
<td>Shelf-Life</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>8</td>
</tr>
<tr>
<td>6</td>
<td>Cost to Implement</td>
<td>4</td>
<td>8</td>
<td>8</td>
<td>4</td>
</tr>
</tbody>
</table>

**Rank each Criteria 2, 4, 6, 8 or 10 on each criterion — no more than two “10” rankings allowed.**

<table>
<thead>
<tr>
<th>Critical Criteria</th>
<th>Recombinant Gene Deleted</th>
<th>Recombinant Vaccinia-vectored</th>
<th>Recombinant Swinepox-Vectored</th>
<th>DNA Vaccine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Efficacy</td>
<td>100</td>
<td>40</td>
<td>40</td>
<td>20</td>
</tr>
<tr>
<td>Safety</td>
<td>64</td>
<td>64</td>
<td>32</td>
<td>80</td>
</tr>
<tr>
<td>One dose</td>
<td>64</td>
<td>48</td>
<td>48</td>
<td>16</td>
</tr>
<tr>
<td>Cross-Protection</td>
<td>16</td>
<td>16</td>
<td>16</td>
<td>16</td>
</tr>
<tr>
<td>Onset of Immunity</td>
<td>60</td>
<td>60</td>
<td>60</td>
<td>20</td>
</tr>
<tr>
<td>Distribution/Supply</td>
<td>32</td>
<td>32</td>
<td>32</td>
<td>32</td>
</tr>
<tr>
<td>Mass Administration</td>
<td>48</td>
<td>48</td>
<td>48</td>
<td>24</td>
</tr>
<tr>
<td>Duration of Immunity</td>
<td>48</td>
<td>36</td>
<td>36</td>
<td>24</td>
</tr>
<tr>
<td>DIVA Compatible</td>
<td>64</td>
<td>64</td>
<td>64</td>
<td>64</td>
</tr>
<tr>
<td>Shelf-Life</td>
<td>36</td>
<td>36</td>
<td>36</td>
<td>48</td>
</tr>
<tr>
<td>Cost to Implement</td>
<td>24</td>
<td>48</td>
<td>36</td>
<td>24</td>
</tr>
<tr>
<td>Value</td>
<td>556</td>
<td>492</td>
<td>448</td>
<td>368</td>
</tr>
</tbody>
</table>

**Major Assumptions:**

**Vaccine Profile**

1. Highly efficacious: prevent transmission; efficacy in all age pigs, cross protection across all ASF viral strains; quick onset of immunity; one year duration of immunity, one shot.
2. Safe in all age pigs; no reversion to virulence for live vaccines
3. DIVA compatible
4. Manufacturing method yields high number of doses
5. Mass vaccination compatible to eliminate individual pig inoculation
6. Rapid speed of production and scale-up
7. Reasonable cost
8. Short withdrawal period for food consumption
9. Long shelf life
10. Distribution and supply (determined on need for diluent and freezer versus refrigerated space)
11. Cost to implement, cost of goods, cost of administration, cost of storage
APPENDIX III: DIAGNOSTICS FOR SURVEILLANCE

SURVEILLANCE: Commercial and reference Diagnostics for African Swine Fever

Major Assumptions for surveillance:

Diagnostic Test Profile
1. Detect all ASFV isolates.
2. Direct and indirect tests.
3. >95% specificity
4. >95% sensitivity
5. Validated
7. Easy to perform
8. Scalable
9. Reasonable cost
10. Pen-side test
11. Expertise

<table>
<thead>
<tr>
<th>Critical Criteria</th>
<th>ELISA K3</th>
<th>ELISA OIE</th>
<th>IB test</th>
<th>IIF test</th>
<th>rttimePCR-King</th>
<th>PCR AGUERO</th>
<th>VI</th>
<th>DIF</th>
<th>Antigen ELISA K2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensitivity</td>
<td>64</td>
<td>64</td>
<td>80</td>
<td>64</td>
<td>48</td>
<td>64</td>
<td>64</td>
<td>48</td>
<td>18</td>
</tr>
<tr>
<td>Specificity</td>
<td>80</td>
<td>60</td>
<td>60</td>
<td>80</td>
<td>80</td>
<td>80</td>
<td>100</td>
<td>80</td>
<td>80</td>
</tr>
<tr>
<td>Validation to purpose</td>
<td>80</td>
<td>80</td>
<td>80</td>
<td>80</td>
<td>100</td>
<td>80</td>
<td>80</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>Speed of Scaleup</td>
<td>48</td>
<td>36</td>
<td>12</td>
<td>24</td>
<td>48</td>
<td>12</td>
<td>12</td>
<td>48</td>
<td>48</td>
</tr>
<tr>
<td>Throughput</td>
<td>48</td>
<td>36</td>
<td>12</td>
<td>12</td>
<td>48</td>
<td>36</td>
<td>12</td>
<td>12</td>
<td>48</td>
</tr>
<tr>
<td>Pen-Side Test</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Rapid Result</td>
<td>48</td>
<td>48</td>
<td>48</td>
<td>48</td>
<td>48</td>
<td>12</td>
<td>12</td>
<td>48</td>
<td>48</td>
</tr>
<tr>
<td>Definitive results</td>
<td>16</td>
<td>16</td>
<td>64</td>
<td>64</td>
<td>32</td>
<td>32</td>
<td>32</td>
<td>16</td>
<td>16</td>
</tr>
<tr>
<td>Easy to perform</td>
<td>48</td>
<td>48</td>
<td>48</td>
<td>24</td>
<td>36</td>
<td>36</td>
<td>12</td>
<td>12</td>
<td>60</td>
</tr>
<tr>
<td>Expertise</td>
<td>60</td>
<td>48</td>
<td>36</td>
<td>12</td>
<td>24</td>
<td>24</td>
<td>12</td>
<td>12</td>
<td>60</td>
</tr>
<tr>
<td>Cost to Implement</td>
<td>8</td>
<td>40</td>
<td>16</td>
<td>32</td>
<td>16</td>
<td>24</td>
<td>24</td>
<td>32</td>
<td>8</td>
</tr>
<tr>
<td>Value</td>
<td>500</td>
<td>476</td>
<td>436</td>
<td>420</td>
<td>460</td>
<td>492</td>
<td>392</td>
<td>424</td>
<td>392</td>
</tr>
</tbody>
</table>
### APPENDIX IV: DIAGNOSTICS FOR RESPONDING TO A DISEASE OUTBREAK

**OUTBREAK: Commercial and Reference Diagnostics for African Swine Fever**

Rank each Intervention (2, 4, 6, 8, or 10) as to its importance to making a decision, only one “10” rankings allowed.

<table>
<thead>
<tr>
<th>Weight</th>
<th>Critical Criteria</th>
<th>ELISA K3</th>
<th>ELISA OIE</th>
<th>IB test</th>
<th>IIF test</th>
<th>timePCR-King</th>
<th>PCR AGÜERO</th>
<th>VI DIF</th>
<th>Antigen ELISA K2</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>Sensitivity</td>
<td>8</td>
<td>8</td>
<td>10</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>6</td>
<td>2</td>
</tr>
<tr>
<td>8</td>
<td>Specificity</td>
<td>8</td>
<td>6</td>
<td>6</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>10</td>
<td>8</td>
</tr>
<tr>
<td>8</td>
<td>Validation to purpose</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>6</td>
<td>8</td>
<td>10</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>8</td>
<td>Speed of Scaleup</td>
<td>8</td>
<td>6</td>
<td>2</td>
<td>4</td>
<td>8</td>
<td>8</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>8</td>
<td>Throughput</td>
<td>8</td>
<td>6</td>
<td>2</td>
<td>2</td>
<td>8</td>
<td>6</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>Pen-Side Test</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>10</td>
<td>Rapid Result</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>10</td>
<td>8</td>
<td>2</td>
<td>8</td>
</tr>
<tr>
<td>6</td>
<td>Definitive results</td>
<td>2</td>
<td>2</td>
<td>8</td>
<td>8</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>8</td>
</tr>
<tr>
<td>6</td>
<td>Easy to perform</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>4</td>
<td>6</td>
<td>6</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>8</td>
<td>Expertise</td>
<td>10</td>
<td>8</td>
<td>6</td>
<td>2</td>
<td>4</td>
<td>4</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>4</td>
<td>Cost to Implement</td>
<td>2</td>
<td>10</td>
<td>4</td>
<td>8</td>
<td>4</td>
<td>6</td>
<td>6</td>
<td>8</td>
</tr>
</tbody>
</table>

Rank each Criteria 2, 4, 6, 8 or 10 on each criterion -- no more than two “10” rankings allowed.

<table>
<thead>
<tr>
<th>Critical Criteria</th>
<th>ELISA K3</th>
<th>ELISA OIE</th>
<th>IB test</th>
<th>IIF Test</th>
<th>timePCR-King</th>
<th>PCR AGÜERO</th>
<th>VI DIF</th>
<th>Antigen ELISA K2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensitivity</td>
<td>80</td>
<td>80</td>
<td>100</td>
<td>80</td>
<td>80</td>
<td>80</td>
<td>80</td>
<td>60</td>
</tr>
<tr>
<td>Specificity</td>
<td>64</td>
<td>48</td>
<td>48</td>
<td>64</td>
<td>64</td>
<td>64</td>
<td>80</td>
<td>64</td>
</tr>
<tr>
<td>Validation to purpose</td>
<td>64</td>
<td>64</td>
<td>64</td>
<td>48</td>
<td>64</td>
<td>80</td>
<td>64</td>
<td>64</td>
</tr>
<tr>
<td>Speed of Scaleup</td>
<td>64</td>
<td>48</td>
<td>16</td>
<td>32</td>
<td>64</td>
<td>16</td>
<td>32</td>
<td>64</td>
</tr>
<tr>
<td>Throughput</td>
<td>64</td>
<td>48</td>
<td>16</td>
<td>16</td>
<td>64</td>
<td>16</td>
<td>16</td>
<td>64</td>
</tr>
<tr>
<td>Pen-Side Test</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Rapid Result</td>
<td>80</td>
<td>80</td>
<td>80</td>
<td>80</td>
<td>100</td>
<td>80</td>
<td>20</td>
<td>80</td>
</tr>
<tr>
<td>Definitive results</td>
<td>12</td>
<td>12</td>
<td>48</td>
<td>48</td>
<td>24</td>
<td>24</td>
<td>48</td>
<td>48</td>
</tr>
<tr>
<td>Easy to perform</td>
<td>48</td>
<td>48</td>
<td>48</td>
<td>24</td>
<td>36</td>
<td>36</td>
<td>12</td>
<td>24</td>
</tr>
<tr>
<td>Expertise</td>
<td>80</td>
<td>64</td>
<td>48</td>
<td>16</td>
<td>32</td>
<td>32</td>
<td>16</td>
<td>16</td>
</tr>
<tr>
<td>Cost to Implement</td>
<td>8</td>
<td>40</td>
<td>16</td>
<td>16</td>
<td>16</td>
<td>16</td>
<td>16</td>
<td>16</td>
</tr>
<tr>
<td>Value</td>
<td>564</td>
<td>532</td>
<td>484</td>
<td>440</td>
<td>544</td>
<td>532</td>
<td>376</td>
<td>436</td>
</tr>
</tbody>
</table>

**Major Assumptions in outbreak:**

**Diagnostic Test Profile**
1. Detect all ASFV isolates.
2. Direct and indirect tests.
3. >95% specificity
4. >95% sensitivity
5. Validated
7. Easy to perform
8. Scalable
9. Reasonable cost
10. Pen-side test
11. Expertise
APPENDIX V: EXPERIMENTAL DIAGNOSTICS FOR SURVEILLANCE

### Surveillance: Experimental Diagnostics for African Swine Fever

<table>
<thead>
<tr>
<th>Critical Criteria</th>
<th>HT-rELISA</th>
<th>p30-rIB</th>
<th>HT-rIB</th>
<th>IPT test</th>
<th>Fast rtimePCR-King</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensitivity</td>
<td>80</td>
<td>64</td>
<td>64</td>
<td>64</td>
<td>64</td>
</tr>
<tr>
<td>Specificity</td>
<td>80</td>
<td>100</td>
<td>100</td>
<td>80</td>
<td>80</td>
</tr>
<tr>
<td>Validation to purpose</td>
<td>80</td>
<td>80</td>
<td>80</td>
<td>80</td>
<td>80</td>
</tr>
<tr>
<td>Speed of Scaleup</td>
<td>48</td>
<td>12</td>
<td>12</td>
<td>24</td>
<td>48</td>
</tr>
<tr>
<td>Throughput</td>
<td>48</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>60</td>
</tr>
<tr>
<td>Pen-Side Test</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Rapid Result</td>
<td>36</td>
<td>48</td>
<td>48</td>
<td>48</td>
<td>48</td>
</tr>
<tr>
<td>Definitive results</td>
<td>16</td>
<td>64</td>
<td>64</td>
<td>64</td>
<td>64</td>
</tr>
<tr>
<td>Easy to perform</td>
<td>36</td>
<td>48</td>
<td>48</td>
<td>12</td>
<td>24</td>
</tr>
<tr>
<td>Expertise</td>
<td>36</td>
<td>48</td>
<td>48</td>
<td>12</td>
<td>24</td>
</tr>
<tr>
<td>Cost to Implement</td>
<td>16</td>
<td>8</td>
<td>8</td>
<td>32</td>
<td>16</td>
</tr>
<tr>
<td>Value</td>
<td>476</td>
<td>484</td>
<td>484</td>
<td>420</td>
<td>516</td>
</tr>
</tbody>
</table>

**Major Assumptions for surveillance:**

**Diagnostic Test Profile**

1. Detect all ASFV isolates.
2. Direct and indirect tests.
3. >95% specificity
4. >95% sensitivity
5. Validated
7. Easy to perform
8. Scalable
9. Reasonable cost
10. Pen-side test
11. Expertise
APPENDIX VI: EXPERIMENTAL DIAGNOSTICS FOR RESPONDING TO A DISEASE OUTBREAK

### Outbreak: Experimental Diagnostics for African Swine Fever

<table>
<thead>
<tr>
<th>Weight</th>
<th>Critical Criteria</th>
<th>HT-rELISA</th>
<th>p30-rIB</th>
<th>HT-rIB</th>
<th>IPT test</th>
<th>Fast rtmePCR-King</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>Sensitivity</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>8</td>
<td>Specificity</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>8</td>
<td>Validation to purpose</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>6</td>
<td>8</td>
</tr>
<tr>
<td>8</td>
<td>Speed of Scaleup</td>
<td>8</td>
<td>2</td>
<td>2</td>
<td>4</td>
<td>8</td>
</tr>
<tr>
<td>8</td>
<td>Throughput</td>
<td>8</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>8</td>
</tr>
<tr>
<td>2</td>
<td>Pen-Side Test</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>10</td>
<td>Rapid Result</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>10</td>
</tr>
<tr>
<td>6</td>
<td>Definitive results</td>
<td>6</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>6</td>
</tr>
<tr>
<td>6</td>
<td>Easy to perform</td>
<td>6</td>
<td>8</td>
<td>8</td>
<td>4</td>
<td>8</td>
</tr>
<tr>
<td>8</td>
<td>Expertise</td>
<td>6</td>
<td>8</td>
<td>8</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>4</td>
<td>Cost to Implement</td>
<td>4</td>
<td>2</td>
<td>2</td>
<td>8</td>
<td>4</td>
</tr>
</tbody>
</table>

Rank each Intervention (2, 4, 6, 8, or 10) as to its importance to making a decision, only one "10" rankings allowed.

### Critical Criteria

<table>
<thead>
<tr>
<th>Critical Criteria</th>
<th>HT-rELISA</th>
<th>p30-rIB</th>
<th>HT-rIB</th>
<th>IPT test</th>
<th>Fast rtmePCR-King</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensitivity</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>80</td>
<td>80</td>
</tr>
<tr>
<td>Specificity</td>
<td>64</td>
<td>64</td>
<td>64</td>
<td>64</td>
<td>64</td>
</tr>
<tr>
<td>Validation to purpose</td>
<td>64</td>
<td>64</td>
<td>64</td>
<td>48</td>
<td>64</td>
</tr>
<tr>
<td>Speed of Scaleup</td>
<td>64</td>
<td>16</td>
<td>16</td>
<td>32</td>
<td>64</td>
</tr>
<tr>
<td>Throughput</td>
<td>64</td>
<td>16</td>
<td>16</td>
<td>16</td>
<td>64</td>
</tr>
<tr>
<td>Pen-Side Test</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Rapid Result</td>
<td>80</td>
<td>80</td>
<td>80</td>
<td>80</td>
<td>100</td>
</tr>
<tr>
<td>Definitive results</td>
<td>36</td>
<td>48</td>
<td>48</td>
<td>48</td>
<td>36</td>
</tr>
<tr>
<td>Easy to perform</td>
<td>36</td>
<td>48</td>
<td>48</td>
<td>24</td>
<td>48</td>
</tr>
<tr>
<td>Expertise</td>
<td>48</td>
<td>64</td>
<td>64</td>
<td>16</td>
<td>32</td>
</tr>
<tr>
<td>Cost to Implement</td>
<td>16</td>
<td>8</td>
<td>8</td>
<td>32</td>
<td>16</td>
</tr>
<tr>
<td>Value</td>
<td>572</td>
<td>508</td>
<td>508</td>
<td>440</td>
<td>568</td>
</tr>
</tbody>
</table>

Rank each Criteria 2, 4, 6, 8 or 10 on each criterion -- no more than two "10" rankings allowed.

Major Assumptions in outbreak:

**Diagnostic Test Profile**

1. Detect all ASFV isolates.
2. Direct and indirect tests.
3. >95% specificity
4. >95% sensitivity
5. Validated
7. Easy to perform
8. Scalable
9. Reasonable cost
10. Pen-side test
11. Expertise
APPENDIX VII: REPORT CONTRIBUTORS

Covadonga Alonso (GARA Chief Executive Officer, 2013-2019)
Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA)
Otra. de la Coruña Km 7,5, Madrid, Spain
Tel: +34 91 347 6896
E-mail: calonso@inia.es

Marisa Arias, Ph.D
Director
Animal Health Research Centre -Centro de Investigación en Sanidad Animal-
EU Reference Laboratory for African Swine Fever
FAO Reference Centre for African Swine Fever
Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA-CISA),
Valdeolmos, 28130, Madrid, SPAIN.
Tel: +34 916202300
Fax:+34 916202247
e-mail: arias@inia.es

Jonathan Arzt, DVM, Ph.D
Veterinary Pathologist
Foreign Animal Disease Unit
Plum Island Animal Disease Center
Agricultural Research Service (ARS)
United States Department of Agriculture (USDA)
P.O. Box 848
Greenport, NY 11944
Tel (631) 631-323-3249
jonathan.arzt@ars.usda.gov

Daniel Beltran-Alcrudo, DVM, Ph.D
Animal Health Officer (veterinary epidemiologist)
FAO, Regional Office for Europe and Central Asia
Mozsár utca 14; 1066 Budapest; Hungary
phone: +36-18141262
E-mail: daniel.beltranalcrudo@fao.org

Amanda Bastos
University of Pretoria
Pretoria, South Africa
Tel: +27 12 4204612
E-mail: ADBastos@zoology.up.ac.za
Richard Bishop, Ph.D
Senior Molecular Biologist
International Livestock Research Institute (ILRI)
PO Box 30709, Old Naivasha Road
Nairobi 00100, Kenya
Telephone: 254 20 422 3000 (switchboard) 422 3359 (direct line)
Fax: 254 20 422 3001
Mobile telephone: 0710 831 851
E-mail: r.bishop@cgiar.org

Sandra Blome, DVM, Ph.D (GARA Scientific Director, 2016-2019)
Friedrich-Loeffler-Institut
Institute of Diagnostic Virology
Suedufer 10
17493 Greifswald – Insel Riems
Germany
Phone: +49-38351-7-1144
E-mail: sandra.blome@fli.de

Prof. Fernando Boinas,
Universidad de Lisboa
E-mail: fboinas@fmv.utl.pt

Manuel V. Borca, D.V.M., Ph.D
Foreign Animal Disease Research Unit
Plum Island Animal Disease Center
Agricultural Research Service (ARS)
United States Department of Agriculture (USDA)
P.O. Box 848 Greenport, NY 11944, USA
Tel. (631) 323 3135
Fax: (631) 323 3006
E-mail: manuel.borca@ars.usda.gov

Bruce Carter, DVM
Global Vaccine Manager
Center for Veterinary Biologics
Licensing and Policy Development
Animal and Plant Inspection Services (APHIS)
United States Department of Agriculture (USDA)
510 S. 17th Street, Suite 104, Ames, IA 50010 USA
Tel (515) 232-5785 Ext. 141
Fax (515) 232-7120
E-mail: bruce.carter@aphis.usda.gov
**Consuelo Carrillo, DVM, PhD**  
Senior Animal Health Advisor  
DSS-FADDL-STATS-VS-NVSL  
APHIS-USDA  
PIADC, PO Box 848, Greenport  
11944 NY  
E-mail: Consuelo.Carrillo@aphis.usda.gov

**Tengiz Chaligava**  
National Food Agency (NFA) of the Ministry of Agriculture (MoA)  
6 Marshal Gelovani Ave  
Tbilisi, Georgia  
E-mail: Tengiz.Chaligava@nfa.gov.ge

**Dave Chapman, Ph.D**  
ASF Virus group  
Institute for Animal Health, Pirbright Laboratory  
Ash Road, Pirbright, Woking  
Surrey, GU24 0NF, UK  
Tel : +44 (0)1483 231084 (Direct Line)  
E-mail: Dave.chapman@bbsrc.ac.uk

**Solenne Costard**  
E-mail: scostard@epixanalytics.com

**Ana De La Torre**  
INIA-CISA  
Ctra Algete - El Casar s/n  
Valdeolmos, Madrid, Spain  
Tel: +34 91 6202300  
E-mail: torre@inia.es

**Linda Dixon (GARA Scientific Director, 2013-2016)**  
Head African swine fever virus group  
Head of OIE ASF Reference Laboratory  
The Pirbright Institute  
Ash Road, Pirbright, Woking, Surrey, UK  
linda.dixon@pirbright.ac.uk

**Tea Enukidze**  
Laboratory of the Ministry of Agriculture  
#49, Vaso Godziashvili street  
Tbilisi, Georgia  
E-mail: tea.enukidze@lma.gov.ge
Eric Etter
Veterinaria Epidemiologist
University Of Pretoria / CIRAD
Private Bag X04. Onderstepoort, South Africa
Tel: +27 (0)12 529 84 67
E-mail: eric.etter@cirad.fr

Folorunso O. Fasina, D.V.M., Ph.D
Department of Veterinary Tropical Diseases, University of Pretoria & Emergency Center for Transboundary Animal Diseases, Food and Agriculture Organization of the United Nations
House H Sida, Ali Hassan Mwinyi Road, Ada Estate
Dar es Salaam, United Republic of Tanzania
P.O. Box 2 Dar es Salaam, Tanzania
Tel. +255 686 132 852
Fax: +255 22 266 7286
E-mail: folorunso.fasina@fao.org

Dr. Jovita Fernández Pinero
EU- Community Reference Laboratory for African Swine Fever
Centro de Investigación en Sanidad Animal – Animal Health Research Center- (CISA)
Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA)
Valdeolmos, 28130
Madrid, Spain
Tel. +3491602300
fpinero@inia.es

Dr. Carmina Gallardo Frontaura
Laboratory Coordinator
EU- Community Reference Laboratory for African Swine Fever
Centro de Investigación en Sanidad Animal – Animal Health Research Center- (CISA)
Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA)
Valdeolmos, 28130
Madrid, Spain
Tel. +3491602300
gallardo@inia.es

Cyril Gerard Gay, DVM, Ph.D (GARA Executive Secretary, 2013-2019)
Senior National Program Leader
Animal Production and Protection
Agricultural Research Service
United States Department of Agriculture
cyril.gay@ars.usda.gov
Dolores Gavier-Widén, DVM, MsC, PhD, Ass. Prof.
Department of Pathology and Wildlife Diseases
Head of Department
National Veterinary Institute (SVA), Sweden
Tel: +46 (0)18-674215 (office),
    +46 703787892 (mobile)
E-mail: dolores@sva.se

Douglas Gladue, Ph.D
Foreign Animal Disease Research Unit
Plum Island Animal Disease Center
Agricultural Research Service (ARS)
United States Department of Agriculture (USDA)
P.O. Box 848 Greenport, NY 11944, USA
Tel. (631) 323 3135
Fax: (631) 323 3006
E-mail: Douglas.Gladue@usda.gov

Ana Gulbani
Laboratory of the Ministry of Agriculture
#49, Vaso Godziashvili street
Tbilisi, Georgia
E-mail: tea.enukidze@lma.gov.ge

Livio Heath (GARA President, 2013-2016)
Onderstepoort Veterinary Institute
South Africa
E-mail: heathl@arc.agric.za

Denis Kolbasov, Ph.D, DVM
Director, Russian National Institute of Veterinary Virology and Microbiology
Pokrov Vladimir region, Russia 601120
Tel/Fax  +7-49243-62125
denvk@land.ru

Marie Frederique LePotier (GARA President, 2016-2019)
Anses – Laboratoire de Ploufragan/Plouzané Laboratory
Swine virology and immunology unit
ZOOPOLE LES CROIX
22440 Ploufragan, France
Tel : +33 (0)2 96 01 62 90
Fax : +33 (0)2 96 01 62 94
Email: marie-frederique.lepotier@anses.fr
Willie Loeffen
Central Veterinary Institute
Houtribweg 39, Lelystad, The Netherlands
Tel: +31 320 238696
E-mail: willie.loeffen@wur.nl

Alexander Malogolovkin
E-mail: Malogolovkin@inbox.ru

Carlos Martins, DVM, Ph.D
Coordinator ASFRISK
Office C4-102
Faculdade de Medicina Veterinária
Av. da Universidade Técnica
1300-477 Lisboa, Portugal
cmartins@fmv.utl.pt

Beatriz Martinez
University of California, Davis
E-mail: beamartinezlopez@ucdavis.edu

Charles Masembe (GARA Finance Director, 2016-2019)
Makerere University
Kampala, Uganda
Tel : +256712455987
E-mail: cmasembe@cns.mak.ac.ug

Dr. Marta Martinez Aviles, UCM-CISA
Universidad Complutense, Facultad de Veterinaria
Avda. Puerta de Hierro
28040 Madrid, Spain
and , Centro de Investigación en Sanidad Animal – Animal Health Research Center- (CISA)
Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA)
Valdeolmos, 28130
Madrid, Spain
Tel. +3491602300
marta@sanidadanimal.info

Ioseb Menteshashvili
National Food Agency (NFA) of the Ministry of Agriculture (MoA)
6 Marshal Gelovani Ave
Tbilisi, Georgia
E-mail: stkhelia@ch2m.com
Gerald Misinzo
Sokoine University of Agriculture
PO Box 3019, Morogoro, Tanzania
Tel: +255767058805
E-mail: gmisinzo@gmail.com

Imbi Nurmoja
Estonian Veterinary and Food Laboratory
Kreutzwaldi 30, Tartu, Estonia
E-mail: imbi.nurmoja@vetlab.ee

Mary-Louise Penrith, PhD, DSc, BVSc (Hons)
Extraordinary Professor
Department of Veterinary Tropical Diseases
Faculty of Veterinary Science
University of Pretoria
South Africa
E-mail: marylouise@vodamail.co.za

Tamas Petrovic, D.V.M. M.Sc. Ph.D.
Scientific Veterinary Institute "Novi Sad"
Director Deputy for research
Rumenacki put 20
21000 Novi Sad
Serbia
Phone: +381 21 4895 321;
Mob: +381 64 818 5410
E-mail: tomy@niv.ns.ac.rs

Fernando Rodriguez
E-mail: fernando.rodriguez@irta.cat

Luis Rodriguez, DVM, Ph.D
Research Leader
Foreign Animal Disease Research Unit
Agricultural Research Service
United States Department of Agriculture
Orient Point, New York
luis.rodriguez@ars.usda.gov

Guillermo Risatti, DVM, Ph.D
University of Connecticut
61 N. Eagleville Road, Unit 3089, Storrs, CT, USA
Tel: +1 860 486 6150
E-mail: guillermo.risatti@uconn.edu
Bob Rowland, Ph.D (GARA Finance Director, 2013-2016)
Kansas State University
1800 Denison Avenue, Manhattan, Kansas, USA
E-mail: browland@vet.k-state.edu

Karl Stahl
National Veterinary Institute (SVA)
Uppsala, Sweden
E-mail: karl.stahl@sva.se

Hermann Unger
IAEA
Vienna, Austria
E-mail: h.unger@iaea.org

Chris Upton, Ph.D
Biochemistry and Microbiology
University of Victoria, Canada
Victoria, BC
Research page: www.virology.ca
Home page: www.virology.ca/node/333
E-mail : cupton@uvic.ca

Dr. Pedro José Sánchez-Cordón,
Fac. Veterinaria, University of Cordoba, Spain
E-mail: an2sacop@uco.es

Isabel Mínguez Tudela, DVM, Ph.D (In memory – deceased)
Scientific Officer
Directorate General Research
European Commission
Office SDME 8/96
1049 Brussels
BELGIUM

Dr. Yolanda Revilla-Novella, Ph.D
Department of Immunology and Virology
Centro de Biología Molecular Severo Ochoa
C/Nicolás Cabrera 1 Campus de la Universidad Autónoma de Madrid
28049-Madrid, Spain
Tel. +34-911964401
vrevilla@cbm.uam.es
Juergen A. Richt, DVM, PhD
Regents Distinguished Professor
Kansas State University
Diagnostic Medicine/Pathobiology Dept.
College of Veterinary Medicine
K224B Mosier Hall
Manhattan, KS 66506-5601
Tel: 785-532-4408
E-mail: mailto:dclouser@vet.k-state.edu

Dr. Paloma Rueda, Ph.D
Research Manager
INGENASA (Inmunología y Genética Aplicada S.A.)
Av/Institución Libre de Enseñanza, 41
28037-Madrid, Spain
Tel. +34-913680501
prueda@ingenasa.com

Dr. Patricia Sastre, Ph.D
Research Department
INGENASA (Inmunología y Genética Aplicada S.A.)
Av/Institución Libre de Enseñanza, 41
28037-Madrid, Spain
Tel. +34-913680501
E-mail: psastre@ingenasa.com

Nino Vepkhvadze
Laboratory of the Ministry of Agriculture
49, Godziashvili Street
Tbilisi, Georgia
E-mail: stkhelia@ch2m.com

Arvo Viltrop
Professor of veterinary epidemiology
Institute of Veterinary Medicine and Animal Science
Estonian University of Life Sciences, Kreutzwaldi 62, Tartu 51014
E-mail: arvo.viltrop@emu.ee
Tel: +372 7313210, +372 5033229

Prof. Dr. José-Manuel Sánchez-Vizcaíno, DVM, Ph.D
Catedrático de Sanidad Animal
Director del Laboratorio de Referencia de la OIE
Universidad Complutense Facultad de Veterinaria
Avda. Puerta de Hierro
28040 Madrid, Spain
jmvizcaino@visavet.ucm.es
Dr. David Williams, Ph.D
Group Leader – Emergency Disease Laboratory Diagnosis
CSIRO Australian Animal Health Laboratory
5 Portarlington Road
Geelong, Victoria
Australia 3220
Tel. +61-3-5227-5364
d.williams@csiro.au

Hovakim Zakaryan
Institute of Molecular Biology
7 Hasratyan, St. Yerevan, Armenia
E-mail: h_zakaryan@mb.sci.am

Laszlo Zsak, DVM, Ph.D (Retired)
Plum Island Animal Disease Center
Agricultural Research Service (ARS)
United Department of Agriculture (USDA)
P.O. Box 848 Greenport, NY 11944, USA
REFERENCES


Keil GM; Goller K; Pollin R; Bishop R; Höper D; Blome S; Portugal R. (2016). Adaptation of African Swine Fever Virus field strains to productively replicate in WSL cells is not necessarily associated with larger deletions within the viral genomes. 3rd Annual GARA scientific workshop. Ploufragan, France. September 6, 2016.


Falls National Park, Uganda, and the Potential Association with African Swine Fever Outbreaks.


Montgomery RE (1921) A form of swine fever occurring in British East Africa (Kenya Colony). J Comp Pathol 34:159–191


Moss A. (2001) Tenacity of viral infectious agents in biogenic waste during co-fermentation with manure. Inaugural dissertation to obtain the doctorate degree at the Department of Veterinary Medicine of Justus Liebig University Giessen; submitted by Andreas Moss, veterinarian from Tübingen, casting 2001, ISBN 3-933953-87-1


Steyn DG (1928) Preliminary report on a South African virus disease amongst pigs. 13th and 14th Reports of the Director of Veterinary Education and Research, Union of South Africa, pp 415–428


